Prestige Consumer Healthcare (PBH) 10-Q 5 Nov 15 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2015	Oct. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	1,295,947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,747,116

Consolidated Statements of Inco

Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues
Net sales	$ 205,262	$ 180,005	$ 396,549	$ 324,546
Other revenues	803	1,264	1,648	2,425
Total revenues	206,065	181,269	398,197	326,971
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	86,125	78,727	166,021	142,563
Gross profit	119,940	102,542	232,176	184,408
Operating Expenses
Advertising and promotion	27,893	25,044	54,315	44,140
General and administrative	16,462	27,128	34,051	44,134
Depreciation and amortization	5,687	3,852	11,407	6,813
Total operating expenses	50,042	56,024	99,773	95,087
Operating income	69,898	46,518	132,403	89,321
Other (income) expense
Interest income	(33)	(15)	(60)	(47)
Interest expense	20,700	18,208	42,611	32,893
Loss on extinguishment of debt	0	0	451	0
Total other expense	20,667	18,193	43,002	32,846
Income before income taxes	49,231	28,325	89,401	56,475
Provision for income taxes	17,428	11,862	31,425	23,280
Net income	$ 31,803	$ 16,463	$ 57,976	$ 33,195
Earnings per share:
Basic (in USD per share)	$ 0.60	$ 0.32	$ 1.10	$ 0.64
Diluted (in USD per share)	$ 0.60	$ 0.31	$ 1.09	$ 0.63
Weighted average shares outstanding:
Basic (in shares)	52,803	52,088	52,676	52,023
Diluted (in shares)	53,151	52,594	53,055	52,564
Comprehensive income, net of tax:
Currency translation adjustments	$ (11,079)	$ (10,830)	$ (11,484)	$ (8,104)
Total other comprehensive loss	(11,079)	(10,830)	(11,484)	(8,104)
Comprehensive income	$ 20,724	$ 5,633	$ 46,492	$ 25,091

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Current assets
Cash and cash equivalents	$ 22,152	$ 21,318
Accounts receivable, net	91,340	87,858
Inventories	77,137	74,000
Deferred income tax assets	8,273	8,097
Prepaid expenses and other current assets	6,877	10,434
Total current assets	205,779	201,707
Property and equipment, net	12,920	13,744
Goodwill	289,061	290,651
Intangible assets, net	2,117,669	2,134,700
Other long-term assets	1,462	1,165
Total Assets	2,626,891	2,641,967
Current liabilities
Accounts payable	41,777	46,115
Accrued interest payable	9,656	11,974
Other accrued liabilities	41,595	40,948
Total current liabilities	93,028	99,037
Long-term debt
Principal amount	1,503,600	1,593,600
Less unamortized debt costs	(31,736)	(32,327)
Long-term debt, net	1,471,864	1,561,273
Deferred income tax liabilities	373,764	351,569
Other long-term liabilities	2,480	2,464
Total Liabilities	$ 1,941,136	$ 2,014,343
Commitments and Contingencies
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	$ 0	$ 0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 53,053 shares at September 30, 2015 and 52,562 shares at March 31, 2015	530	525
Additional paid-in capital	439,861	426,584
Treasury stock, at cost - 306 shares at September 30, 2015 and 266 shares at March 31, 2015	(5,121)	(3,478)
Accumulated other comprehensive loss, net of tax	(34,896)	(23,412)
Retained earnings	285,381	227,405
Total Stockholders' Equity	685,755	627,624
Total Liabilities and Stockholders' Equity	$ 2,626,891	$ 2,641,967

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2015	Mar. 31, 2015
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	53,053,000	52,562,000
Treasury stock, shares	306,000	266,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Operating Activities
Net income	$ 57,976	$ 33,195
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	11,407	6,815
Deferred income taxes	21,985	11,496
Amortization of debt origination costs	4,055	3,085
Stock-based compensation costs	5,034	3,403
Loss on extinguishment of debt	451	0
Loss (gain) on sale or disposal of property and equipment	(36)	56
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	(3,918)	(8,363)
Inventories	(3,838)	7,264
Prepaid expenses and other current assets	3,436	3,114
Accounts payable	(4,519)	(5,647)
Accrued liabilities	(1,443)	2,640
Net cash provided by operating activities	90,590	57,058
Investing Activities
Purchases of property and equipment	(1,683)	(1,380)
Proceeds from the sale of property and equipment	344	0
Proceeds from sale of business	0	18,500
Acquisition of Insight Pharmaceuticals, less cash acquired		(749,666)
Acquisition of the Hydralyte brand		(77,991)
Net cash used in investing activities	(1,339)	(810,537)
Financing Activities
Term loan borrowings	0	720,000
Term loan repayments	(50,000)	(25,000)
Borrowings under revolving credit agreement	15,000	124,600
Repayments under revolving credit agreement	(55,000)	(58,500)
Payments of debt origination costs	(4,211)	(16,072)
Proceeds from exercise of stock options	6,398	2,757
Proceeds from restricted stock exercises	544	57
Excess tax benefits from share-based awards	1,850	1,030
Fair value of shares surrendered as payment of tax withholding	(2,187)	(1,660)
Net cash (used in) provided by financing activities	(87,606)	747,212
Effects of exchange rate changes on cash and cash equivalents	(811)	(316)
Increase (decrease) in cash and cash equivalents	834	(6,583)
Cash and cash equivalents - beginning of period	21,318	28,331
Cash and cash equivalents - end of period	22,152	21,748
Interest paid	40,550	27,349
Income taxes paid	3,707	4,716
Insight Pharmaceuticals
Investing Activities
Acquisition of the Hydralyte brand	0	(749,666)
Hydralyte
Investing Activities
Acquisition of the Hydralyte brand	$ 0	$ (77,991)

Business and Basis of Presentat

Business and Basis of Presentation	6 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 9 to these Consolidated Financial Statements. Basis of Presentation The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in these Consolidated Financial Statements. In the opinion of management, these Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2016”) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three and six months ended September 30, 2015 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2016 . These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015 . Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate. Cash and Cash Equivalents We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at September 30, 2015 are uninsured. Accounts Receivable We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance. Inventories Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence. Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * * Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Goodwill The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level. Intangible Assets Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Debt Origination Costs We have incurred debt origination costs in connection with the issuance of long-term debt. Certain of these costs were recorded as deferred financing costs within long-term assets and others were recorded as a reduction to our long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our term loan facility and the straight-line method for our revolving credit facility. Effective April 1, 2015, in accordance with new accounting standards discussed below, we began reporting the costs related to our senior notes and the term loan facility as a reduction of debt. We continue to report the costs associated with our revolving credit facility as a long-term asset. Revenue Recognition Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience. As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results. Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising. Cost of Sales Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Shipping, warehousing and handling costs were $10.4 million and $19.1 million for the three and six months ended September 30, 2015 , respectively, and $9.4 million and $17.1 million for the three and six months ended September 30, 2014 , respectively. Advertising and Promotion Costs Advertising and promotion costs are expensed as incurred. Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees. Stock-based Compensation We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period. Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our tax uncertainties. We are subject to taxation in the United States and various state and foreign jurisdictions. We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income. Earnings Per Share Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, and unvested restricted stock units, are included in the earnings per share calculation to the extent that they are dilutive. Recently Issued Accounting Standards In September 2015, the FASB issued Accounting Standards Update ("ASU") 2015-16, Simplifying the Accounting for Measurement-Period Adjustments . The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. To simplify the accounting for adjustment made to provisional amounts recognized in a business combination, the amendments in this update eliminate the requirement to retrospectively account for those adjustments. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The adoption of ASU 2015-16 is not expected to have a material impact on our Consolidated Financial Statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory . The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs ("ASU 2015-03"). The amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. As permitted by the guidance, we have early adopted these provisions, as of the beginning of our first quarter of 2016. Given the absence of authoritative guidance within ASU 2015-03 for debt issuance costs related to line-of-credit arrangements, in August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements , stating that the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement . As a result, we reclassified $27.4 million of deferred financing costs as of March 31, 2015 from other long-term assets, and such costs are now presented as a direct deduction from the long-term debt liability. In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis . Update 2015-02 amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendments in this update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-02 is not expected to have a material impact on our Consolidated Financial Statements. In January 2015, the FASB issued ASU 2015-01, Income Statement - Extraordinary and Unusual Items . The amendments in this update eliminate the concept of extraordinary items in Subtopic 225-20, which required entities to consider whether an underlying event or transaction is extraordinary. However, the amendments retain the presentation and disclosure guidance for items that are unusual in nature or occur infrequently. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The adoption of ASU 2015-01 is not expected to have a material impact on our Consolidated Financial Statements. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606 , which supersedes the revenue recognition requirements in FASB Accounting Standards Codification ("ASC") 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity . Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 did not have a material impact on our Consolidated Financial Statements. Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Acquisitions

Acquisitions	6 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Acquisitions	Acquisitions Acquisition of Insight Pharmaceuticals On September 3, 2014, the Company completed the acquisition of Insight Pharmaceuticals Corporation ("Insight"), a marketer and distributor of feminine care and other OTC healthcare products, for $753.2 million in cash. The closing followed the Federal Trade Commission’s (“FTC”) approval of the acquisition and was finalized pursuant to the terms of the purchase agreement announced on April 25, 2014. Pursuant to the Insight purchase agreement, the Company acquired 27 OTC brands sold in North America (including related trademarks, contracts and inventory), which extended the Company's portfolio of OTC brands to include a leading feminine care platform in the United States and Canada anchored by Monistat , the leading brand in OTC yeast infection treatment. The acquisition also added brands to the Company's cough & cold, pain relief, ear care and dermatological platforms. In connection with the FTC's approval of the Insight acquisition, we sold one of the competing brands that we acquired from Insight on the same day as the Insight closing. The Insight brands are primarily included in our North American OTC Healthcare segment. The Insight acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. During the quarter ended June 30, 2015, we adjusted the fair values of the assets acquired and liabilities assumed for certain immaterial items that came to our attention subsequent to the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date. (In thousands) September 3, 2014 Cash acquired $ 3,507 Accounts receivable 26,012 Inventories 23,456 Deferred income tax assets - current 1,032 Prepaids and other current assets 1,341 Property, plant and equipment 2,308 Goodwill 103,560 Intangible assets 724,374 Total assets acquired 885,590 Accounts payable 16,079 Accrued expenses 8,539 Deferred income tax liabilities - long term 107,799 Total liabilities assumed 132,417 Total purchase price $ 753,173 Based on this analysis, we allocated $ 599.6 million to indefinite-lived intangible assets and $ 124.8 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 16.2 years. The weighted average remaining life for amortizable intangible assets at September 30, 2015 was 15.1 years. We also recorded goodwill of $ 103.6 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes. The operating results of Insight have been included in our Consolidated Financial Statements beginning September 3, 2014. On September 3, 2014, we sold one of the brands we acquired from the Insight acquisition for $18.5 million , for which we had allocated $17.7 million , $0.6 million and $0.2 million to intangible assets, inventory and property, plant and equipment, respectively. The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results. (In thousands, except per share data) Six Months Ended September 30, 2014 Revenues $ 393,140 Net income $ 37,957 Earnings per share: Basic $ 0.73 Diluted $ 0.72 Acquisition of the Hydralyte brand On April 30, 2014, we completed the acquisition of the Hydralyte brand in Australia and New Zealand from The Hydration Pharmaceuticals Trust of Victoria, Australia, which was funded through a combination of cash on hand and our existing senior secured credit facility. Hydralyte is the leading OTC brand in oral rehydration in Australia and is marketed and sold through our Care Pharmaceuticals Pty Ltd. subsidiary ("Care Pharma"). Hydralyte is available in pharmacies in multiple forms and is indicated for oral rehydration following diarrhea, vomiting, fever, heat and other ailments. Hydralyte is included in our International OTC Healthcare segment. The Hydralyte acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date. (In thousands) April 30, 2014 Inventories $ 1,970 Property, plant and equipment, net 1,267 Goodwill 1,224 Intangible assets, net 73,580 Total assets acquired 78,041 Accrued expenses 38 Other long-term liabilities 12 Total liabilities assumed 50 Net assets acquired $ 77,991 Based on this analysis, we allocated $73.6 million to non-amortizable intangible assets and no allocation was made to amortizable intangible assets. We also recorded goodwill of $1.2 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes. The pro forma effect of this acquisition on revenues and earnings was not material.

Accounts Receivable

Accounts Receivable	6 Months Ended
	Sep. 30, 2015
Receivables [Abstract]
Accounts Receivable	Accounts Receivable Accounts receivable consist of the following: (In thousands) September 30, March 31, Components of Accounts Receivable Trade accounts receivable $ 99,324 $ 95,411 Other receivables 1,745 2,353 101,069 97,764 Less allowances for discounts, returns and uncollectible accounts (9,729 ) (9,906 ) Accounts receivable, net $ 91,340 $ 87,858

Inventories

Inventories	6 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: (In thousands) September 30, March 31, Components of Inventories Packaging and raw materials $ 6,428 $ 7,588 Finished goods 70,709 66,412 Inventories $ 77,137 $ 74,000 Inventories are carried and depicted above at the lower of cost or market value, which includes a reduction in inventory values of $3.5 million and $4.1 million at September 30, 2015 and March 31, 2015 , respectively, related to obsolete and slow-moving inventory.

Property and Equipment

Property and Equipment	6 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consist of the following: (In thousands) September 30, March 31, Components of Property and Equipment Machinery $ 4,056 $ 4,743 Computer equipment 13,300 11,339 Furniture and fixtures 2,373 2,484 Leasehold improvements 7,336 7,134 27,065 25,700 Accumulated depreciation (14,145 ) (11,956 ) Property and equipment, net $ 12,920 $ 13,744 We recorded depreciation expense of $1.2 million and $0.9 million for the three months ended September 30, 2015 and 2014, respectively, and $2.5 million and $1.6 million for the six months ended September 30, 2015 and 2014, respectively.

Goodwill

Goodwill	6 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC Healthcare International OTC Healthcare Household Cleaning Consolidated Balance — March 31, 2015 $ 263,411 $ 20,440 $ 6,800 $ 290,651 Adjustments 305 — — 305 Effects of foreign currency exchange rates — (1,895 ) — (1,895 ) Balance — September 30, 2015 $ 263,716 $ 18,545 $ 6,800 $ 289,061 As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and recorded goodwill of $103.6 million , reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of net assets acquired. During the quarter ended June 30, 2015, we adjusted the fair values of the assets acquired and liabilities assumed by $0.3 million for certain immaterial items that came to our attention subsequent to the date of acquisition. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and recorded goodwill of $1.2 million , reflecting the amount by which the purchase price exceeded the preliminary estimate of fair value of the net assets acquired. Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. At February 28, 2015 , during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in fiscal 2015. As of September 30, 2015, there have been no triggering events that would indicate potential impairment of goodwill.

Intangible Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets A reconciliation of the activity affecting intangible assets is as follows: (In thousands) Indefinite Lived Trademarks Finite Lived Trademarks Totals Gross Carrying Amounts Balance — March 31, 2015 $ 1,873,404 $ 358,066 $ 2,231,470 Effects of foreign currency exchange rates (7,988 ) (129 ) (8,117 ) Balance — September 30, 2015 1,865,416 357,937 2,223,353 Accumulated Amortization Balance — March 31, 2015 — 96,770 96,770 Additions — 8,933 8,933 Effects of foreign currency exchange rates — (19 ) (19 ) Balance — September 30, 2015 — 105,684 105,684 Intangible assets, net - September 30, 2015 $ 1,865,416 $ 252,253 $ 2,117,669 Intangible Assets, net by Reportable Segment: North American OTC Healthcare $ 1,676,991 $ 227,627 $ 1,904,618 International OTC Healthcare 78,153 1,076 79,229 Household Cleaning 110,272 23,550 133,822 Intangible assets, net - September 30, 2015 $ 1,865,416 $ 252,253 $ 2,117,669 As discussed in Note 2, we completed two acquisitions during the year ended March 31, 2015. On September 3, 2014, we completed the acquisition of Insight and allocated $724.4 million to intangible assets based on our preliminary analysis. Additionally, on April 30, 2014, we completed the acquisition of the Hydralyte brand and allocated $73.6 million to intangible assets based on our preliminary analysis. Furthermore, on September 3, 2014, we sold one of the brands that we acquired from Insight, for which we had allocated $17.7 million to intangible assets. Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value. On an annual basis during the fourth fiscal quarter, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment. We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test and the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. We also considered our market capitalization at February 28, 2015 , which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future. As a result of recent declines in revenues in Pediacare and in certain other brands, we continue to monitor whether events or conditions would indicate that the fair value of the intangible asset no longer exceeds the carrying value. Although we continue to believe that the fair values of our brands exceed their carrying values, sustained or significant future declines in revenue, profitability, lost distribution, other adverse changes in expected operating results, and/or unfavorable changes in other economic factors used to estimate fair value of certain brands could indicate that the fair value no longer exceeds carrying value, in which case a non-cash impairment charge may be recorded in future periods. The weighted average remaining life for finite-lived intangible assets at September 30, 2015 was approximately 14.1 years, and the amortization expense for the three and six months ended September 30, 2015 was $4.4 million and $8.9 million , respectively. At September 30, 2015 , finite-lived intangible assets are being amortized over a period of 10 to 30 years, and the associated amortization expense is expected to be as follows: (In thousands) Year Ending March 31, Amount 2016 (Remaining six months ending March 31, 2016) $ 8,933 2017 17,867 2018 17,867 2019 17,867 2020 17,867 Thereafter 171,852 $ 252,253

Other Accrued Liabilities

Other Accrued Liabilities	6 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) September 30, March 31, Accrued marketing costs $ 20,909 $ 16,903 Accrued compensation costs 4,655 8,840 Accrued broker commissions 1,082 1,134 Income taxes payable 2,936 2,642 Accrued professional fees 2,214 2,769 Deferred rent 945 1,021 Accrued production costs 5,170 5,610 Accrued lease termination costs 607 669 Other accrued liabilities 3,077 1,360 $ 41,595 $ 40,948

Long-Term Debt

Long-Term Debt	6 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt 2012 Senior Notes: On January 31, 2012, Prestige Brands, Inc. (the "Borrower") issued $250.0 million of senior unsecured notes at par value, with an interest rate of 8.125% and a maturity date of February 1, 2020 (the "2012 Senior Notes"). The Borrower may earlier redeem some or all of the 2012 Senior Notes at redemption prices set forth in the indenture governing the 2012 Senior Notes. The 2012 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2012 Senior Notes offering, we incurred $12.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2012 Senior Notes. 2012 Term Loan and 2012 ABL Revolver: On January 31, 2012, the Borrower also entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a 7 -year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a 5 -year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25% . The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million . In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. On February 21, 2013, the Borrower entered into Amendment No. 1 (the "Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loans"). The interest rate on the Term B-1 Loans under the Term Loan Amendment No. 1 was based, at the Borrower's option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin. The new Term B-1 Loans mature on the same date as the Term B Loans' original maturity date. In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the 2012 Senior Notes and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt. On September 3, 2014, the Borrower entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provided for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loans") in an aggregate principal amount of $720.0 million , (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on (x) the Term B-1 Loans that was based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin, and (y) the Term B-2 Loans that was based, at the Borrower’s option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio). On May 8, 2015, the Borrower entered into Amendment No. 3 (the "Term Loan Amendment No. 3") to the 2012 Term Loan. Term Loan Amendment No. 3 provides for (i) the creation of a new class of Term B-3 Loans under the 2012 Term Loan (the "Term B-3 Loans") in an aggregate principal amount of $852.5 million , which combined the outstanding balances of the Term B-1 Loans of $207.5 million and the Term B-2 Loans of $645.0 million , (ii) increased flexibility under the credit agreement governing the 2012 Term Loan, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on the Term B-3 Loans that is based, at the Borrower’s option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 0.75% , or an alternate base rate, with a floor of 1.75% , plus a margin. The maturity date of the Term B-3 Loans remains the same as the Term B-2 Loans' original maturity date of September 3, 2021. The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50% , (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 1.75% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 0.75% . For the six months ended September 30, 2015 , the average interest rate on the 2012 Term Loan was 4.6% . Under the 2012 Term Loan, we were originally required to make quarterly payments each equal to 0.25% of the original principal amount of the 2012 Term Loan, with the balance expected to be due on the seventh anniversary of the closing date. However, since we entered into Term Loan Amendment No. 3, we are required to make quarterly payments each equal to 0.25% of the aggregate principal amount of $852.5 million . Since we have previously made optional payments that exceeded a significant portion of our required quarterly payments, we will not be required to make another payment until the fiscal year ending March 31, 2019. On September 3, 2014, the Borrower entered into Amendment No. 3 (“ABL Amendment No. 3”) to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin plus, at the Borrower's option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50% , (b) the prime rate of Citibank, N.A., or (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The initial applicable margin for borrowings under the 2012 ABL Revolver is 1.75% with respect to LIBOR borrowings and 0.75% with respect to base-rate borrowings. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. On June 9, 2015, the Borrower entered into Amendment No. 4 (“ABL Amendment No. 4”) to the 2012 ABL Revolver. ABL Amendment No. 4 provides for (i) a $35.0 million increase in the accordion feature under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief and (iii) extended the maturity date of the 2012 ABL Revolver to June 9, 2020, which is five years from the effective date. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the six months ended September 30, 2015 , the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.2% . 2013 Senior Notes: On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes. Redemptions and Restrictions: At any time prior to February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of the notes redeemed, plus a "make-whole premium" calculated as set forth in the indenture governing the 2012 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after February 1, 2016, we may redeem the 2012 Senior Notes in whole or in part at redemption prices set forth in the indenture governing the 2012 Senior Notes. In addition, at any time prior to February 1, 2015, we could have redeemed up to 35% of the aggregate principal amount of the 2012 Senior Notes at a redemption price equal to 108.125% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions were met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2012 Senior Notes, the Borrower will be required to make an offer to purchase the 2012 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2012 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. At any time prior to December 15, 2016, we may redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we may redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2013 Senior Notes, the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. The indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2012 Senior Notes and the 2013 Senior Notes. At September 30, 2015 , we were in compliance with the covenants under our long-term indebtedness. Effective April 1, 2015, the Company elected to change its method of presentation relating to debt issuance costs in accordance with ASU 2015-03. Prior to 2016, the Company's policy was to present these costs in other-long term assets on the balance sheet, net of accumulated amortization. Beginning in 2016, the Company has presented these fees as a direct deduction to the related long-term debt. As a result, we reclassified $27.4 million of deferred financing costs as of March 31, 2015 from other long-term assets, and such costs are now presented as a direct deduction from the long-term debt liability. At September 30, 2015, we had an aggregate of $31.7 million of unamortized debt costs, the total of which is comprised of $7.9 million related to the 2012 Senior Notes, $5.9 million related to the 2013 Senior Notes and $17.9 million related to the 2012 Term Loan. As of September 30, 2015, we had $26.1 million outstanding on the 2012 ABL Revolver and a borrowing capacity of $87.2 million . Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) September 30, March 31, 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. $ 400,000 $ 400,000 2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020. 250,000 250,000 2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021. 827,500 877,500 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020. 26,100 66,100 Total long-term debt (including current portion) 1,503,600 1,593,600 Current portion of long-term debt — — Long-term debt 1,503,600 1,593,600 Less: unamortized debt costs (31,736 ) (32,327 ) Long-term debt, net $ 1,471,864 $ 1,561,273 As of September 30, 2015, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows: (In thousands) Year Ending March 31, Amount 2016 (remaining six months ending March 31, 2016) $ — 2017 — 2018 — 2019 6,969 2020 258,525 Thereafter 1,238,106 $ 1,503,600

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. The Fair Value Measurements and Disclosures topic of the FASB ASC 820 requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2013 Senior Notes, the 2012 Senior Notes, the Term B-3 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. At September 30, 2015 and March 31, 2015 , we did not have any assets or liabilities measured in Level 1 or 3. During the periods presented, there were no transfers of assets or liabilities between Levels 1, 2 and 3. At September 30, 2015 and March 31, 2015 , the carrying value of our 2013 Senior Notes was $400.0 million . The fair value of our 2013 Senior Notes was $391.0 million and $405.0 million at September 30, 2015 and March 31, 2015 , respectively. At September 30, 2015 and March 31, 2015 , the carrying value of our 2012 Senior Notes was $250.0 million . The fair value of our 2012 Senior Notes was $263.8 million and $268.1 million at September 30, 2015 and March 31, 2015 , respectively. At September 30, 2015 and March 31, 2015 , the carrying value of the Term B-3 Loans was $827.5 million and $877.5 million , respectively. The fair value of the Term B-3 Loans was $827.5 million and $880.5 million at September 30, 2015 and March 31, 2015 , respectively. At September 30, 2015 and March 31, 2015 , the carrying value of the 2012 ABL Revolver was $26.1 million and $66.1 million , respectively. The fair value of the 2012 ABL revolver was $26.0 million and $65.7 million at September 30, 2015 and March 31, 2015, respectively.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through September 30, 2015 . During the three and six months ended September 30, 2015 , we repurchased 0 shares and 39,429 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. During the three and six months ended September 30, 2014, we repurchased 13,924 shares and 47,664 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the six months ended September 30, 2015 and 2014 were at an average price of $41.66 and $33.63 , respectively. All of the repurchased shares have been recorded as treasury stock.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The table below presents accumulated other comprehensive loss (“AOCI”), which affects equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. AOCI consisted of the following at September 30, 2015 and March 31, 2015 : September 30, March 31, (In thousands) 2015 2015 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (34,896 ) $ (23,412 ) Accumulated other comprehensive loss, net of tax $ (34,896 ) $ (23,412 )

Earnings Per Share

Earnings Per Share	6 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options, and restricted stock units. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, (In thousands, except per share data) 2015 2014 2015 2014 Numerator Net income $ 31,803 $ 16,463 $ 57,976 $ 33,195 Denominator Denominator for basic earnings per share — weighted average shares outstanding 52,803 52,088 52,676 52,023 Dilutive effect of unvested restricted stock units and options issued to employees and directors 348 506 379 541 Denominator for diluted earnings per share 53,151 52,594 53,055 52,564 Earnings per Common Share: Basic net earnings per share $ 0.60 $ 0.32 $ 1.10 $ 0.64 Diluted net earnings per share $ 0.60 $ 0.31 $ 1.09 $ 0.63 For the three months ended September 30, 2015 and 2014, there were 0.2 million and 0.3 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For the six months ended September 30, 2015 and 2014, there were 0.2 million and 0.3 million shares, respectively, attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, the stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, increased the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any 12-month period from 1.0 million to 2.5 million shares, and extended the term of the Plan by ten years to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan. During the three and six months ended September 30, 2015 , pre-tax share-based compensation costs charged against income were $2.0 million and $5.0 million , respectively, and the related income tax benefit recognized was $0.7 million and $1.8 million , respectively. During the three and six months ended September 30, 2014 , pre-tax share-based compensation costs charged against income were $1.5 million and $3.4 million , respectively, and the related income tax benefit recognized was $0.5 million and $1.2 million , respectively. On April 22, 2015, we announced that Matthew M. Mannelly, our President and Chief Executive Officer and member of the Board of Directors, would retire effective June 1, 2015. In conjunction with his retirement, the Board of Directors accelerated the vesting of his previously unvested restricted stock units and stock options, and we recorded additional compensation expense of approximately $0.8 million associated with this acceleration. Effective June 1, 2015, the Board of Directors appointed Ron Lombardi, our then current Chief Financial Officer, to succeed Mr. Mannelly as President and Chief Executive Officer and as a member of the Board of Directors. In connection with his appointment, Mr. Lombardi was granted 57,924 restricted stock units on April 22, 2015. On May 11, 2015, the Compensation Committee of our Board of Directors (the "Compensation Committee") granted 185,904 restricted stock units and stock options to acquire 186,302 shares of our common stock to certain executive officers and employees under the Plan. Of those grants, 163,404 restricted stock units vest in their entirety on the three -year anniversary of the date of grant and 22,500 restricted stock units vest 33.3% per year over three years. Upon vesting, the units will be settled in shares of our common stock. The stock options vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $41.44 per share, which is equal to the closing price of our common stock on the date of grant. On July 1, 2015, the Compensation Committee granted 2,841 restricted stock units, which vest on the three -year anniversary of the date of grant, and stock options to acquire 13,861 shares of our common stock to certain employees under the Plan. The stock options vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $46.58 per share, which is equal to the closing price of our common stock on the date of grant. Restricted Shares Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The restricted share awards provide for accelerated vesting if there is a change of control, as defined in the Plan. The restricted stock units granted to employees generally vest in their entirety on the three -year anniversary of the date of the grant. Termination of employment prior to vesting will result in forfeiture of the restricted stock units, unless otherwise accelerated by the Compensation Committee of the Board of Directors. The restricted stock units granted to directors vest in their entirety one year after the date of grant so long as the membership on the Board of Directors continues through the vesting date, with the settlement in common stock to occur on the earliest of the director's death, disability or six-month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. Upon vesting, the units will be settled in shares of our common stock. Each of our six independent members of the Board of Directors received a grant of 2,075 restricted stock units on August 4, 2015 under the Plan. Additionally, on May 11, 2015, the Compensation Committee granted 362 restricted stock units to a newly appointed Board member. The restricted stock units vest on the one year anniversary of the date of grant and will be settled by delivery to the director of one share of common stock of the Company for each vested restricted stock unit promptly following the earliest of the director's (i) death, (ii) disability or (iii) the six -month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. The fair value of the restricted stock units is determined using the closing price of our common stock on the date of the grant. The weighted-average grant-date fair value during the six months ended September 30, 2015 and 2014 was $42.20 and $33.30 , respectively. A summary of the Company's restricted shares granted under the Plan is presented below: Restricted Shares Shares (in thousands) Weighted- Average Grant-Date Fair Value Six months ended September 30, 2014 Vested and nonvested at March 31, 2014 437.5 $ 16.76 Granted 104.4 33.30 Vested and issued (120.7 ) 13.34 Forfeited (14.4 ) 20.78 Vested and nonvested at September 30, 2014 406.8 21.88 Vested at September 30, 2014 76.6 11.62 Six months ended September 30, 2015 Vested and nonvested at March 31, 2015 362.3 $ 22.74 Granted 259.5 42.20 Vested and issued (153.6 ) 18.16 Forfeited (1.4 ) 33.50 Vested and nonvested at September 30, 2015 466.8 35.03 Vested at September 30, 2015 69.8 14.76 Options The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms in the Plan. The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management's estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options. The weighted-average grant-date fair values of the options granted during the six months ended September 30, 2015 and 2014 was $17.10 and $15.93 , respectively. Six Months Ended September 30, 2015 2014 Expected volatility 40.2 % 47.3 % Expected dividends $ — $ — Expected term in years 6.0 6.0 Risk-free rate 1.7 % 2.2 % A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Six months ended September 30, 2014: Outstanding at March 31, 2014 994.9 $ 15.24 Granted 307.5 33.50 Exercised (284.4 ) 9.70 Forfeited or expired (32.5 ) 25.61 Outstanding at September 30, 2014 985.5 22.19 8.0 $ 10,364 Exercisable at September 30, 2014 416.0 14.31 6.8 7,514 Six months ended September 30, 2015: Outstanding at March 31, 2015 871.2 $ 23.40 Granted 200.1 41.80 Exercised (336.9 ) 18.99 Forfeited or expired (2.1 ) 38.16 Outstanding at September 30, 2015 732.3 30.42 8.1 $ 10,816 Exercisable at September 30, 2015 319.5 21.91 7.0 7,430 The aggregate intrinsic value of options exercised in the six months ended September 30, 2015 was $8.3 million . At September 30, 2015 , there were $13.3 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 1.2 years. The total fair value of options and restricted shares vested during the six months ended September 30, 2015 and 2014 was $6.5 million and $4.2 million , respectively. For the six months ended September 30, 2015 and 2014, cash received from the exercise of stock options was $6.4 million and $2.8 million , respectively, and we realized $2.0 million and $1.8 million , respectively, in tax benefits from the tax deductions resulting from these option exercises. At September 30, 2015 , there were 2.6 million shares available for issuance under the Plan.

Income Taxes

Income Taxes	6 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 35.4% and 41.9% for the three months ended September 30, 2015 and 2014, respectively. The effective tax rates used in the calculation of income taxes were 35.2% and 41.2% for the six months ended September 30, 2015 and 2014, respectively. The decrease in the effective tax rate for the three and six months ended September 30, 2015 was primarily due to the impact of certain non-deductible items related to acquisitions in the prior year period and to favorable tax deductions related to stock options and equity awards that were realized in the current year period. At September 30, 2015 , 100% owned subsidiaries of the Company had net operating loss carryforwards of approximately $44.6 million , which may be used to offset future taxable income of the consolidated group and which begin to expire in 2020. The net operating loss carryforwards are subject to an annual limitation as to usage of approximately $33.6 million pursuant to Internal Revenue Code Section 382. The Company expects to utilize all of the net operating loss carryforwards before they expire. The balance in our uncertain tax liability was $3.4 million at September 30, 2015 and March 31, 2015. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in any of the periods presented.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not be material to our financial condition or results of operations. Lease Commitments We have operating leases for office facilities and equipment in New York, Wyoming, and other locations, which expire at various dates through fiscal 2021. These amounts have been included in the table below. The following summarizes future minimum lease payments for our operating leases as of September 30, 2015 (a) : (In thousands) Year Ending March 31, Facilities Equipment Total 2016 (Remaining six months ending March 31, 2016) $ 887 $ 95 $ 982 2017 1,861 77 1,938 2018 1,871 — 1,871 2019 1,864 — 1,864 2020 1,695 — 1,695 Thereafter 770 — 770 $ 8,948 $ 172 $ 9,120 (a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.3 million due in the future under noncancelable subleases. The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals: (In thousands) September 30, 2015 March 31, 2015 Minimum lease payments $ 9,120 $ 9,957 Less: Sublease rentals (1,283 ) (1,401 ) $ 7,837 $ 8,556 Rent expense for the three months ended September 30, 2015 and 2014 was $0.4 million and $0.3 million , respectively. Rent expense for the six months ended September 30, 2015 and 2014 was $0.8 million and $0.7 million , respectively. Purchase Commitments Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement. (In thousands) Year Ending March 31, Amount 2016 (Remaining six months ending March 31, 2016) 533 2017 1,044 2018 1,013 2019 982 2020 560 Thereafter — $ 4,132

Concentrations of Risk

Concentrations of Risk	6 Months Ended
	Sep. 30, 2015
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and convenience, dollar and club stores. During the three and six months ended September 30, 2015 , approximately 41.7% and 42.8% , respectively, of our total revenues were derived from our five top selling brands. During the three and six months ended September 30, 2014 , approximately 40.6% and 41.2% , respectively, of our total revenues were derived from our five top selling brands. One customer, Walmart, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 19.6% and 19.7% , respectively, of our gross revenues for the three and six months ended September 30, 2015 , and approximately 17.0% and 18.0% , respectively, of our gross revenues for the three and six months ended September 30, 2014 . Our next largest customer accounted for approximately 10.0% and 9.7% , respectively, of gross revenues for the three and six months ended September 30, 2015. At September 30, 2015 , approximately 20.9% of accounts receivable were owed by Walmart. We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center and inventory levels. As a result, any such disruption could have a material adverse effect on our business, sales and profitability. At September 30, 2015 , we had relationships with 102 third-party manufacturers. Of those, we had long-term contracts with 48 manufacturers that produced items that accounted for approximately 81.3% of gross sales for the six months ended September 30, 2015 . At September 30, 2014 , we had relationships with 101 third-party manufacturers. Of those, we had long-term contracts with 47 manufacturers that produced items that accounted for approximately 77.4% of gross sales for the six months ended September 30, 2014 . The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results from operations. Although we are in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

Business Segments	6 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Business Segments	Business Segments Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses. The tables below summarize information about our reportable segments. Three Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 165,407 $ 17,433 $ 23,894 $ 206,734 Elimination of intersegment revenues (1,472 ) — — (1,472 ) Third-party segment revenues 163,935 17,433 23,894 205,262 Other revenues 6 — 797 803 Total segment revenues 163,941 17,433 24,691 206,065 Cost of sales 61,499 6,092 18,534 86,125 Gross profit 102,442 11,341 6,157 119,940 Advertising and promotion 24,440 2,777 676 27,893 Contribution margin $ 78,002 $ 8,564 $ 5,481 92,047 Other operating expenses 22,149 Operating income 69,898 Other expense 20,667 Income before income taxes 49,231 Provision for income taxes 17,428 Net income $ 31,803 Six Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 321,746 $ 31,642 $ 45,361 $ 398,749 Elimination of intersegment revenues (2,200 ) — — (2,200 ) Third-party segment revenues 319,546 31,642 45,361 396,549 Other revenues 46 — 1,602 1,648 Total segment revenues 319,592 31,642 46,963 398,197 Cost of sales 119,625 11,382 35,014 166,021 Gross profit 199,967 20,260 11,949 232,176 Advertising and promotion 47,635 5,500 1,180 54,315 Contribution margin $ 152,332 $ 14,760 $ 10,769 177,861 Other operating expenses 45,458 Operating income 132,403 Other expense 43,002 Income before income taxes 89,401 Provision for income taxes 31,425 Net income $ 57,976 Three Months Ended September 30, 2014 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 138,318 $ 17,151 $ 25,246 $ 180,715 Elimination of intersegment revenues (710 ) — — (710 ) Third-party segment revenues 137,608 17,151 25,246 180,005 Other revenues 150 23 1,091 1,264 Total segment revenues 137,758 17,174 26,337 181,269 Cost of sales 52,186 6,601 19,940 78,727 Gross profit 85,572 10,573 6,397 102,542 Advertising and promotion 21,441 3,036 567 25,044 Contribution margin $ 64,131 $ 7,537 $ 5,830 77,498 Other operating expenses 30,980 Operating income 46,518 Other expense 18,193 Income before income taxes 28,325 Provision for income taxes 11,862 Net income $ 16,463 Six Months Ended September 30, 2014 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 249,291 $ 30,843 $ 45,839 $ 325,973 Elimination of intersegment revenues (1,427 ) — — (1,427 ) Third-party segment revenues 247,864 30,843 45,839 324,546 Other revenues 327 58 2,040 2,425 Total segment revenues 248,191 30,901 47,879 326,971 Cost of sales 94,526 11,679 36,358 142,563 Gross profit 153,665 19,222 11,521 184,408 Advertising and promotion 37,794 5,375 971 44,140 Contribution margin $ 115,871 $ 13,847 $ 10,550 140,268 Other operating expenses 50,947 Operating income 89,321 Other expense 32,846 Income before income taxes 56,475 Provision for income taxes 23,280 Net income $ 33,195 The tables below summarize information about our segment revenues from similar product groups. Three Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,694 $ 688 $ — $ 30,382 Cough & Cold 24,456 4,746 — 29,202 Women's Health 33,607 804 — 34,411 Gastrointestinal 19,061 5,342 — 24,403 Eye & Ear Care 22,690 5,051 — 27,741 Dermatologicals 23,197 611 — 23,808 Oral Care 9,733 189 — 9,922 Other OTC 1,503 2 — 1,505 Household Cleaning — — 24,691 24,691 Total segment revenues $ 163,941 $ 17,433 $ 24,691 $ 206,065 Six Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 56,542 $ 1,218 $ — $ 57,760 Cough & Cold 44,215 9,252 — 53,467 Women's Health 66,515 1,504 — 68,019 Gastrointestinal 39,381 9,150 — 48,531 Eye & Ear Care 47,022 8,981 — 56,003 Dermatologicals 43,292 1,145 — 44,437 Oral Care 19,710 383 — 20,093 Other OTC 2,915 9 — 2,924 Household Cleaning — — 46,963 46,963 Total segment revenues $ 319,592 $ 31,642 $ 46,963 $ 398,197 Three Months Ended September 30, 2014 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,072 $ 792 $ — $ 29,864 Cough & Cold 24,771 5,461 — 30,232 Women's Health 9,119 658 — 9,777 Gastrointestinal 21,075 5,420 — 26,495 Eye & Ear Care 21,405 4,028 — 25,433 Dermatologicals 17,460 687 — 18,147 Oral Care 12,934 127 — 13,061 Other OTC 1,922 1 — 1,923 Household Cleaning — — 26,337 26,337 Total segment revenues $ 137,758 $ 17,174 $ 26,337 $ 181,269 Six Months Ended September 30, 2014 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 54,103 $ 1,457 $ — $ 55,560 Cough & Cold 44,814 10,259 — 55,073 Women's Health 9,487 1,176 — 10,663 Gastrointestinal 41,713 7,917 — 49,630 Eye & Ear Care 42,130 8,670 — 50,800 Dermatologicals 29,720 1,229 — 30,949 Oral Care 23,121 189 — 23,310 Other OTC 3,103 4 — 3,107 Household Cleaning — — 47,879 47,879 Total segment revenues $ 248,191 $ 30,901 $ 47,879 $ 326,971 During the three months ended September 30, 2015 and 2014, approximately 85.8% and 82.7% , respectively, of our total segment revenues were from customers in the United States. During the six months ended September 30, 2015 and 2014, approximately 86.5% and 83.5% , respectively, of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three months ended September 30, 2015, our Canada and Australia sales accounted for approximately 5.5% and 6.8% , respectively, of our total segment revenues, while during the three months ended September 30, 2014, approximately 7.4% and 8.1% , respectively, of our total segment revenues were attributable to sales to Canada and Australia. During the six months ended September 30, 2015, our Canada and Australia sales accounted for approximately 5.3% and 6.3% , respectively, of our total segment revenues, while during the six months ended September 30, 2014, approximately 6.6% and 7.6% , respectively, of our total segment revenues were attributable to sales to Canada and Australia. At September 30, 2015 , approximately 95.9% of our consolidated goodwill and intangible assets were located in the United States and approximately 4.1% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: (In thousands) North American OTC International OTC Household Cleaning Consolidated Goodwill $ 263,716 $ 18,545 $ 6,800 $ 289,061 Intangible assets Indefinite-lived 1,676,991 78,153 110,272 1,865,416 Finite-lived 227,627 1,076 23,550 252,253 Intangible assets, net 1,904,618 79,229 133,822 2,117,669 Total $ 2,168,334 $ 97,774 $ 140,622 $ 2,406,730

Condensed Consolidating Financi

Condensed Consolidating Financial Statements	6 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Financial Statements	Condensed Consolidating Financial Statements As described in Note 9, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2013 Senior Notes and the 2012 Senior Notes, including the obligation to pay principal and interest with respect to the 2013 Senior Notes and the 2012 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2013 Senior Notes and the 2012 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, Blacksmith Brands, Inc., Insight Pharmaceuticals Corporation, Insight Pharmaceuticals, LLC and Practical Health Products, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2013 Senior Notes and the 2012 Senior Notes. Although holders of the 2013 Senior Notes and the 2012 Senior Notes will be direct creditors of the guarantors of the 2013 Senior Notes and the 2012 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2013 Senior Notes or the 2012 Senior Notes, and such subsidiaries will not be obligated with respect to the 2013 Senior Notes or the 2012 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2013 Senior Notes and the 2012 Senior Notes. Presented below are supplemental Condensed Consolidating Balance Sheets as of September 30, 2015 and March 31, 2015 , Condensed Consolidating Statements of Income and Comprehensive Income for the three and six months ended September 30, 2015 and 2014 , and Condensed Consolidating Statements of Cash Flows for the six months ended September 30, 2015 and 2014 . Such consolidating information includes separate columns for: a) Prestige Brands Holdings, Inc., the parent, b) Prestige Brands, Inc., the Issuer or the Borrower, c) Combined Subsidiary Guarantors, d) Combined Non-Guarantor Subsidiaries, and e) Elimination entries necessary to consolidate the Company and all of its subsidiaries. The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q. Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,957 $ 164,772 $ 14,005 $ (1,472 ) $ 205,262 Other revenues — 79 798 543 (617 ) 803 Total revenues — 28,036 165,570 14,548 (2,089 ) 206,065 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 10,868 72,120 4,952 (1,815 ) 86,125 Gross profit — 17,168 93,450 9,596 (274 ) 119,940 Operating Expenses Advertising and promotion — 3,204 21,933 2,756 — 27,893 General and administrative 1,199 1,300 12,912 1,051 — 16,462 Depreciation and amortization 1,030 147 4,447 63 — 5,687 Total operating expenses 2,229 4,651 39,292 3,870 — 50,042 Operating income (loss) (2,229 ) 12,517 54,158 5,726 (274 ) 69,898 Other (income) expense Interest income (12,161 ) (21,607 ) (1,169 ) (126 ) 35,030 (33 ) Interest expense 8,964 20,303 25,294 1,169 (35,030 ) 20,700 Equity in (income) loss of subsidiaries (31,441 ) (19,746 ) (3,385 ) — 54,572 — Total other (income) expense (34,638 ) (21,050 ) 20,740 1,043 54,572 20,667 Income (loss) before income taxes 32,409 33,567 33,418 4,683 (54,846 ) 49,231 Provision for income taxes 606 4,892 10,632 1,298 — 17,428 Net income (loss) $ 31,803 $ 28,675 $ 22,786 $ 3,385 $ (54,846 ) $ 31,803 Comprehensive income, net of tax: Currency translation adjustments (11,079 ) (11,079 ) (11,079 ) (11,079 ) 33,237 (11,079 ) Total other comprehensive income (loss) (11,079 ) (11,079 ) (11,079 ) (11,079 ) 33,237 (11,079 ) Comprehensive income (loss) $ 20,724 $ 17,596 $ 11,707 $ (7,694 ) $ (21,609 ) $ 20,724 Condensed Consolidating Statements of Income and Comprehensive Income Six Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 55,840 $ 317,296 $ 25,613 $ (2,200 ) $ 396,549 Other revenues — 175 1,617 1,041 (1,185 ) 1,648 Total revenues — 56,015 318,913 26,654 (3,385 ) 398,197 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 21,309 138,498 9,360 (3,146 ) 166,021 Gross profit — 34,706 180,415 17,294 (239 ) 232,176 Operating Expenses Advertising and promotion — 5,721 43,161 5,433 — 54,315 General and administrative 2,514 3,855 24,863 2,819 — 34,051 Depreciation and amortization 2,019 293 8,892 203 — 11,407 Total operating expenses 4,533 9,869 76,916 8,455 — 99,773 Operating income (loss) (4,533 ) 24,837 103,499 8,839 (239 ) 132,403 Other (income) expense Interest income (24,210 ) (43,015 ) (2,389 ) (238 ) 69,792 (60 ) Interest expense 17,454 42,211 50,349 2,389 (69,792 ) 42,611 Loss on extinguishment of debt — 451 — — — 451 Equity in (income) loss of subsidiaries (56,747 ) (36,701 ) (4,835 ) — 98,283 — Total other (income) expense (63,503 ) (37,054 ) 43,125 2,151 98,283 43,002 Income (loss) before income taxes 58,970 61,891 60,374 6,688 (98,522 ) 89,401 Provision for income taxes 994 8,917 19,661 1,853 — 31,425 Net income (loss) $ 57,976 $ 52,974 $ 40,713 $ 4,835 $ (98,522 ) $ 57,976 Comprehensive income, net of tax: Currency translation adjustments (11,484 ) (11,484 ) (11,484 ) (11,484 ) 34,452 (11,484 ) Total other comprehensive income (loss) (11,484 ) (11,484 ) (11,484 ) (11,484 ) 34,452 (11,484 ) Comprehensive income (loss) $ 46,492 $ 41,490 $ 29,229 $ (6,649 ) $ (64,070 ) $ 46,492 Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended September 30, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,167 $ 138,336 $ 15,212 $ (710 ) $ 180,005 Other revenues — 95 1,241 436 (508 ) 1,264 Total revenues — 27,262 139,577 15,648 (1,218 ) 181,269 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 10,426 64,812 5,767 (2,278 ) 78,727 Gross profit — 16,836 74,765 9,881 1,060 102,542 Operating Expenses Advertising and promotion — 2,699 19,311 3,034 — 25,044 General and administrative 1,109 3,441 20,329 2,249 — 27,128 Depreciation and amortization 870 145 2,729 108 — 3,852 Total operating expenses 1,979 6,285 42,369 5,391 — 56,024 Operating income (loss) (1,979 ) 10,551 32,396 4,490 1,060 46,518 Other (income) expense Interest income (12,245 ) (16,719 ) (1,760 ) (11 ) 30,720 (15 ) Interest expense 8,629 18,208 20,333 1,758 (30,720 ) 18,208 Equity in (income) loss of subsidiaries (17,577 ) (9,825 ) (1,870 ) — 29,272 — Total other (income) expense (21,193 ) (8,336 ) 16,703 1,747 29,272 18,193 Income (loss) before income taxes 19,214 18,887 15,693 2,743 (28,212 ) 28,325 Provision for income taxes 2,751 3,262 4,976 873 — 11,862 Net income (loss) $ 16,463 $ 15,625 $ 10,717 $ 1,870 $ (28,212 ) $ 16,463 Comprehensive income, net of tax: Currency translation adjustments (10,830 ) (10,830 ) (10,830 ) (10,830 ) 32,490 (10,830 ) Total other comprehensive income (loss) (10,830 ) (10,830 ) (10,830 ) (10,830 ) 32,490 (10,830 ) Comprehensive income (loss) $ 5,633 $ 4,795 $ (113 ) $ (8,960 ) $ 4,278 $ 5,633 Condensed Consolidating Statements of Income and Comprehensive Income Six Months Ended September 30, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 52,577 $ 247,234 $ 26,163 $ (1,428 ) $ 324,546 Other revenues — 225 2,340 838 (978 ) 2,425 Total revenues — 52,802 249,574 27,001 (2,406 ) 326,971 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 19,874 115,327 9,790 (2,428 ) 142,563 Gross profit — 32,928 134,247 17,211 22 184,408 Operating Expenses Advertising and promotion — 5,388 33,377 5,375 — 44,140 General and administrative 2,254 5,914 29,319 6,647 — 44,134 Depreciation and amortization 1,512 290 4,818 193 — 6,813 Total operating expenses 3,766 11,592 67,514 12,215 — 95,087 Operating income (loss) (3,766 ) 21,336 66,733 4,996 22 89,321 Other (income) expense Interest income (24,378 ) (30,944 ) (2,522 ) (40 ) 57,837 (47 ) Interest expense 17,177 32,893 38,138 2,522 (57,837 ) 32,893 Equity in (income) loss of subsidiaries (33,256 ) (20,723 ) (911 ) — 54,890 — Total other (income) expense (40,457 ) (18,774 ) 34,705 2,482 54,890 32,846 Income (loss) before income taxes 36,691 40,110 32,028 2,514 (54,868 ) 56,475 Provision for income taxes 3,496 6,979 11,202 1,603 — 23,280 Net income (loss) $ 33,195 $ 33,131 $ 20,826 $ 911 $ (54,868 ) $ 33,195 Comprehensive income, net of tax: Currency translation adjustments (8,104 ) (8,104 ) (8,104 ) (8,104 ) 24,312 (8,104 ) Total other comprehensive income (loss) (8,104 ) (8,104 ) (8,104 ) (8,104 ) 24,312 (8,104 ) Comprehensive income (loss) $ 25,091 $ 25,027 $ 12,722 $ (7,193 ) $ (30,556 ) $ 25,091 Condensed Consolidating Balance Sheet September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 10,554 $ — $ — $ 11,598 $ — $ 22,152 Accounts receivable, net — 12,810 70,300 8,230 — 91,340 Inventories — 9,684 62,371 6,467 (1,385 ) 77,137 Deferred income tax assets 281 750 6,863 379 — 8,273 Prepaid expenses and other current assets 2,565 543 3,078 691 — 6,877 Total current assets 13,400 23,787 142,612 27,365 (1,385 ) 205,779 Property and equipment, net 9,918 243 2,210 549 — 12,920 Goodwill — 66,007 204,510 18,544 — 289,061 Intangible assets, net — 192,057 1,846,203 79,409 — 2,117,669 Other long-term assets — 1,462 — — — 1,462 Intercompany receivables 1,224,520 2,539,960 822,065 10,880 (4,597,425 ) — Investment in subsidiary 1,588,050 1,253,751 61,703 — (2,903,504 ) — Total Assets $ 2,835,888 $ 4,077,267 $ 3,079,303 $ 136,747 $ (7,502,314 ) $ 2,626,891 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,254 $ 7,453 $ 29,846 $ 2,224 $ — $ 41,777 Accrued interest payable — 9,656 — — — 9,656 Other accrued liabilities 7,875 2,377 27,132 4,211 — 41,595 Total current liabilities 10,129 19,486 56,978 6,435 — 93,028 Long-term debt Principal amount — 1,503,600 — — — 1,503,600 Less unamortized debt costs — (31,736 ) — — — (31,736 ) Long-term debt, net — 1,471,864 — — — 1,471,864 Deferred income tax liabilities — 59,368 314,376 20 — 373,764 Other long-term liabilities — — 2,333 147 — 2,480 Intercompany payables 2,140,004 1,007,264 1,377,646 72,511 (4,597,425 ) — Total Liabilities 2,150,133 2,557,982 1,751,333 79,113 (4,597,425 ) 1,941,136 Stockholders' Equity Common stock 530 — — — — 530 Additional paid-in capital 439,861 1,280,947 1,131,578 74,031 (2,486,556 ) 439,861 Treasury stock, at cost (5,121 ) — — — — (5,121 ) Accumulated other comprehensive income (loss), net of tax (34,896 ) (34,896 ) (34,896 ) (34,896 ) 104,688 (34,896 ) Retained earnings (accumulated deficit) 285,381 273,234 231,288 18,499 (523,021 ) 285,381 Total Stockholders' Equity 685,755 1,519,285 1,327,970 57,634 (2,904,889 ) 685,755 Total Liabilities and Stockholders' Equity $ 2,835,888 $ 4,077,267 $ 3,079,303 $ 136,747 $ (7,502,314 ) $ 2,626,891 Condensed Consolidating Balance Sheet March 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 11,387 $ — $ — $ 9,931 $ — $ 21,318 Accounts receivable, net — 14,539 66,523 6,796 — 87,858 Inventories — 8,667 60,297 6,182 (1,146 ) 74,000 Deferred income tax assets 452 674 6,497 474 — 8,097 Prepaid expenses and other current assets 5,731 141 3,804 758 — 10,434 Total current assets 17,570 24,021 137,121 24,141 (1,146 ) 201,707 Property and equipment, net 10,726 175 2,207 636 — 13,744 Goodwill — 66,007 204,205 20,439 — 290,651 Intangible assets, net — 192,325 1,854,798 87,577 — 2,134,700 Other long-term assets — 1,165 — — — 1,165 Intercompany receivables 1,210,017 2,607,054 668,169 8,764 (4,494,004 ) — Investment in subsidiary 1,545,575 1,228,535 65,564 — (2,839,674 ) — Total Assets $ 2,783,888 $ 4,119,282 $ 2,932,064 $ 141,557 $ (7,334,824 ) $ 2,641,967 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 1,959 $ 6,829 $ 32,898 $ 4,429 $ — $ 46,115 Accrued interest payable — 11,974 — — — 11,974 Other accrued liabilities 10,378 1,153 25,795 3,622 — 40,948 Total current liabilities 12,337 19,956 58,693 8,051 — 99,037 Long-term debt Principal amount — 1,593,600 — — — 1,593,600 Less unamortized debt costs — (32,327 ) — — — (32,327 ) Long-term debt, net — 1,561,273 — — — 1,561,273 Deferred income tax liabilities — 59,038 292,504 27 — 351,569 Other long-term liabilities — — 2,293 171 — 2,464 Intercompany payables 2,143,927 1,001,219 1,279,833 69,025 (4,494,004 ) — Total Liabilities 2,156,264 2,641,486 1,633,323 77,274 (4,494,004 ) 2,014,343 Stockholders' Equity Common stock 525 — — — — 525 Additional paid-in capital 426,584 1,280,948 1,131,578 74,031 (2,486,557 ) 426,584 Treasury stock, at cost (3,478 ) — — — — (3,478 ) Accumulated other comprehensive income (loss), net of tax (23,412 ) (23,412 ) (23,412 ) (23,412 ) 70,236 (23,412 ) Retained earnings (accumulated deficit) 227,405 220,260 190,575 13,664 (424,499 ) 227,405 Total Stockholders' Equity 627,624 1,477,796 1,298,741 64,283 (2,840,820 ) 627,624 Total Liabilities and Stockholders' Equity $ 2,783,888 $ 4,119,282 $ 2,932,064 $ 141,557 $ (7,334,824 ) $ 2,641,967 Condensed Consolidating Statement of Cash Flows Six Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 57,976 $ 52,974 $ 40,713 $ 4,835 $ (98,522 ) $ 57,976 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 2,019 293 8,892 203 — 11,407 Deferred income taxes 171 254 21,506 54 — 21,985 Amortization of debt origination costs — 4,055 — — — 4,055 Stock-based compensation costs 4,993 — — 41 — 5,034 Loss on extinguishment of debt — 451 — — — 451 Loss (gain) on sale or disposal of property and equipment — — — (36 ) — (36 ) Equity in income of subsidiaries (56,747 ) (36,701 ) (4,835 ) — 98,283 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — 1,729 (3,550 ) (2,097 ) — (3,918 ) Inventories — (1,017 ) (2,177 ) (883 ) 239 (3,838 ) Prepaid expenses and other current assets 3,166 (402 ) 660 12 — 3,436 Accounts payable 269 624 (3,343 ) (2,069 ) — (4,519 ) Accrued liabilities (2,503 ) (1,094 ) 1,012 1,142 — (1,443 ) Net cash provided by operating activities 9,344 21,166 58,878 1,202 — 90,590 Investing Activities Purchases of property and equipment (1,107 ) (93 ) (103 ) (380 ) — (1,683 ) Proceeds from the sale of property and equipment — — — 344 — 344 Net cash used in investing activities (1,107 ) (93 ) (103 ) (36 ) — (1,339 ) Financing Activities Term loan repayments — (50,000 ) — — — (50,000 ) Borrowings under revolving credit agreement — 15,000 — — — 15,000 Repayments under revolving credit agreement — (55,000 ) — — — (55,000 ) Payments of debt origination costs — (4,211 ) — — — (4,211 ) Proceeds from exercise of stock options 6,398 — — — — 6,398 Proceeds from restricted stock exercises 544 — — — — 544 Excess tax benefits from share-based awards 1,850 — — — — 1,850 Fair value of shares surrendered as payment of tax withholding (2,187 ) — — — — (2,187 ) Intercompany activity, net (15,675 ) 73,138 (58,775 ) 1,312 — — Net cash (used in) provided by financing activities (9,070 ) (21,073 ) (58,775 ) 1,312 — (87,606 ) Effect of exchange rate changes on cash and cash equivalents — — — (811 ) — (811 ) (Decrease) increase in cash and cash equivalents (833 ) — — 1,667 — 834 Cash and cash equivalents - beginning of period 11,387 — — 9,931 — 21,318 Cash and cash equivalents - end of period $ 10,554 $ — $ — $ 11,598 $ — $ 22,152 Condensed Consolidating Statement of Cash Flows Six Months Ended September 30, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 33,195 $ 33,131 $ 20,826 $ 911 $ (54,868 ) $ 33,195 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 1,512 290 4,818 195 — 6,815 Deferred income taxes (879 ) 1,351 11,084 (60 ) — 11,496 Amortization of debt origination costs — 3,085 — — — 3,085 Stock-based compensation costs 3,403 — — — — 3,403 Loss (gain) on sale or disposal of property and equipment — — — 56 — 56 Equity in income of subsidiaries (33,256 ) (20,723 ) (911 ) — 54,890 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable 466 (107 ) (4,496 ) (4,226 ) — (8,363 ) Inventories — 4,691 1,857 738 (22 ) 7,264 Prepaid expenses and other current assets 5,163 (241 ) (1,718 ) (90 ) — 3,114 Accounts payable (2,332 ) 1,850 (6,997 ) 1,832 — (5,647 ) Accrued liabilities (1,321 ) 3,313 (701 ) 1,349 — 2,640 Net cash provided by operating activities 5,951 26,640 23,762 705 — 57,058 Investing Activities Purchases of property and equipment (1,127 ) — (87 ) (166 ) — (1,380 ) Proceeds from sale of business — — 18,500 — — 18,500 Acquisition of Insight Pharmaceuticals, less cash acquired — — (749,666 ) — — (749,666 ) Acquisition of the Hydralyte brand — — — (77,991 ) — (77,991 ) Intercompany activity, net — (809,157 ) 731,166 77,991 — — Net cash used in investing activities (1,127 ) (809,157 ) (87 ) (166 ) — (810,537 ) Financing Activities Term loan borrowings — 720,000 — — — 720,000 Term loan repayments — (25,000 ) — — — (25,000 ) Borrowings under revolving credit agreement — 124,600 — — — 124,600 Repayments under revolving credit agreement — (58,500 ) — — — (58,500 ) Payment of debt origination costs — (16,072 ) — — — (16,072 ) Proceeds from exercise of stock options 2,757 — — — — 2,757 Proceeds from restricted stock exercises 57 — — — — 57 Excess tax benefits from share-based awards 1,030 — — — — 1,030 Fair value of shares surrendered as payment of tax withholding (1,660 ) — — — — (1,660 ) Intercompany activity, net (21,187 ) 37,489 (18,641 ) 2,339 — — Net cash provided by (used in) financing activities (19,003 ) 782,517 (18,641 ) 2,339 — 747,212 Effect of exchange rate changes on cash and cash equivalents — — — (316 ) — (316 ) (Decrease) increase in cash and cash equivalents (14,179 ) — 5,034 2,562 — (6,583 ) Cash and cash equivalents - beginning of period 24,644 — — 3,687 — 28,331 Cash and cash equivalents - end of period $ 10,465 $ — $ 5,034 $ 6,249 $ — $ 21,748

Subsequent Events

Subsequent Events	6 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Appointment of Chief Financial Officer: On October 28, 2015, we announced that David Marberger has been appointed as Chief Financial Officer of the Company, effective November 10, 2015. Mr. Marberger will report to Ronald M. Lombardi, who has been serving as both Chief Executive Officer and Chief Financial Officer of the Company since June 1, 2015. In connection with Mr. Marberger’s appointment as Chief Financial Officer, on October 28, 2015, the Company entered into an employment agreement with Mr. Marberger, which sets forth the terms of his compensation as approved by the Compensation Committee of the Board of Directors. In accordance with the terms of his employment agreement, on October 28, 2015, the Company granted to Mr. Marberger, 6,612 shares of restricted common stock units and stock options to acquire 8,079 shares of our common stock under the Plan. The shares of restricted common stock units vest in their entirety on the three -year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $50.42 per share, which is equal to the closing price of our common stock on the day of grant.

Business and Basis of Present26

Business and Basis of Presentation (Policies)	6 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in these Consolidated Financial Statements. In the opinion of management, these Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2016”) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three and six months ended September 30, 2015 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2016 . These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2015 .
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ materially from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships.
Accounts Receivable	Accounts Receivable We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.
Inventories	Inventories Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * * Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
Goodwill	Goodwill The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level.
Intangible Assets	Intangible Assets Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
Debt Origination Costs	Debt Origination Costs We have incurred debt origination costs in connection with the issuance of long-term debt. Certain of these costs were recorded as deferred financing costs within long-term assets and others were recorded as a reduction to our long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our term loan facility and the straight-line method for our revolving credit facility. Effective April 1, 2015, in accordance with new accounting standards discussed below, we began reporting the costs related to our senior notes and the term loan facility as a reduction of debt. We continue to report the costs associated with our revolving credit facility as a long-term asset.
Revenue Recognition	Revenue Recognition Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience. As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results. Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.
Cost of Sales	Cost of Sales Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.
Advertising and Promotion Costs	Advertising and Promotion Costs Advertising and promotion costs are expensed as incurred. Allowances for new distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.
Stock-based Compensation	Stock-based Compensation We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.
Income Taxes	Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our tax uncertainties. We are subject to taxation in the United States and various state and foreign jurisdictions. We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.
Earnings Per Share	Earnings Per Share Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options, and unvested restricted stock units, are included in the earnings per share calculation to the extent that they are dilutive.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In September 2015, the FASB issued Accounting Standards Update ("ASU") 2015-16, Simplifying the Accounting for Measurement-Period Adjustments . The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. To simplify the accounting for adjustment made to provisional amounts recognized in a business combination, the amendments in this update eliminate the requirement to retrospectively account for those adjustments. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The adoption of ASU 2015-16 is not expected to have a material impact on our Consolidated Financial Statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory . The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs ("ASU 2015-03"). The amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. As permitted by the guidance, we have early adopted these provisions, as of the beginning of our first quarter of 2016. Given the absence of authoritative guidance within ASU 2015-03 for debt issuance costs related to line-of-credit arrangements, in August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements , stating that the SEC staff would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement, regardless of whether there are any outstanding borrowings on the line-of-credit arrangement . As a result, we reclassified $27.4 million of deferred financing costs as of March 31, 2015 from other long-term assets, and such costs are now presented as a direct deduction from the long-term debt liability. In February 2015, the FASB issued ASU 2015-02, Amendments to the Consolidation Analysis . Update 2015-02 amended the process that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendments in this update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-02 is not expected to have a material impact on our Consolidated Financial Statements. In January 2015, the FASB issued ASU 2015-01, Income Statement - Extraordinary and Unusual Items . The amendments in this update eliminate the concept of extraordinary items in Subtopic 225-20, which required entities to consider whether an underlying event or transaction is extraordinary. However, the amendments retain the presentation and disclosure guidance for items that are unusual in nature or occur infrequently. The amendments in this update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The adoption of ASU 2015-01 is not expected to have a material impact on our Consolidated Financial Statements. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This amendment states that in connection with preparing financial statements for each annual and interim reporting period, an entity's management should evaluate whether there are conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued, when applicable). The amendments in this update are effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The adoption of ASU 2014-15 is not expected to have a material impact on our Consolidated Financial Statements. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide that a Performance Target Could Be Achieved after the Requisite Service Period, which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. As such, the new guidance does not allow for a performance target that affects vesting to be reflected in estimating the fair value of the award at the grant date. The amendments to this update are effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted. Entities may apply the amendments in this update either prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. We currently do not have any outstanding share-based payments with a performance target. The adoption of ASU 2014-12 is not expected to have a material impact on our Consolidated Financial Statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606 , which supersedes the revenue recognition requirements in FASB Accounting Standards Codification ("ASC") 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity . Under the new guidance, only disposals representing a strategic shift in operations should be presented as discontinued operations. Those strategic shifts should have a major effect on the organization’s operations and financial results. Examples include a disposal of a major geographic area, a major line of business, or a major equity method investment. In addition, the new guidance requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. Early adoption is permitted, but only for disposals (or classifications as held for sale) that have not been reported in financial statements previously issued or available for issuance. The amendments in this update must be applied prospectively to all disposals (or classifications as held for sale) of components of an entity that occur within annual periods beginning on or after December 15, 2014, and interim periods within those years. The adoption of ASU 2014-08 did not have a material impact on our Consolidated Financial Statements. Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on our consolidated financial position, results of operations or cash flows.

Business and Basis of Present27

Business and Basis of Presentation (Tables)	6 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Property and Equipment	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * * Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Property and equipment consist of the following: (In thousands) September 30, March 31, Components of Property and Equipment Machinery $ 4,056 $ 4,743 Computer equipment 13,300 11,339 Furniture and fixtures 2,373 2,484 Leasehold improvements 7,336 7,134 27,065 25,700 Accumulated depreciation (14,145 ) (11,956 ) Property and equipment, net $ 12,920 $ 13,744

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Sep. 30, 2015
Insight Pharmaceuticals
Business Acquisition [Line Items]
Allocation of Assets Acquired and Liabilities Assumed	The following table summarizes our allocation of the assets acquired and liabilities assumed as of the September 3, 2014 acquisition date. (In thousands) September 3, 2014 Cash acquired $ 3,507 Accounts receivable 26,012 Inventories 23,456 Deferred income tax assets - current 1,032 Prepaids and other current assets 1,341 Property, plant and equipment 2,308 Goodwill 103,560 Intangible assets 724,374 Total assets acquired 885,590 Accounts payable 16,079 Accrued expenses 8,539 Deferred income tax liabilities - long term 107,799 Total liabilities assumed 132,417 Total purchase price $ 753,173
Business Acquisition, Pro Forma Information	The following table provides our unaudited pro forma revenues, net income and net income per basic and diluted common share had the results of Insight's operations been included in our operations commencing on April 1, 2013, based upon available information related to Insight's operations. This pro forma information is not necessarily indicative either of the combined results of operations that actually would have been realized by us had the Insight acquisition been consummated at the beginning of the period for which the pro forma information is presented, or of future results. (In thousands, except per share data) Six Months Ended September 30, 2014 Revenues $ 393,140 Net income $ 37,957 Earnings per share: Basic $ 0.73 Diluted $ 0.72
Hydralyte
Business Acquisition [Line Items]
Allocation of Assets Acquired and Liabilities Assumed	The following table summarizes our allocation of the assets acquired and liabilities assumed as of the April 30, 2014 acquisition date. (In thousands) April 30, 2014 Inventories $ 1,970 Property, plant and equipment, net 1,267 Goodwill 1,224 Intangible assets, net 73,580 Total assets acquired 78,041 Accrued expenses 38 Other long-term liabilities 12 Total liabilities assumed 50 Net assets acquired $ 77,991

Accounts Receivable (Tables)

Accounts Receivable (Tables)	6 Months Ended
	Sep. 30, 2015
Receivables [Abstract]
Accounts Receivable	Accounts receivable consist of the following: (In thousands) September 30, March 31, Components of Accounts Receivable Trade accounts receivable $ 99,324 $ 95,411 Other receivables 1,745 2,353 101,069 97,764 Less allowances for discounts, returns and uncollectible accounts (9,729 ) (9,906 ) Accounts receivable, net $ 91,340 $ 87,858

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: (In thousands) September 30, March 31, Components of Inventories Packaging and raw materials $ 6,428 $ 7,588 Finished goods 70,709 66,412 Inventories $ 77,137 $ 74,000

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * * Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Property and equipment consist of the following: (In thousands) September 30, March 31, Components of Property and Equipment Machinery $ 4,056 $ 4,743 Computer equipment 13,300 11,339 Furniture and fixtures 2,373 2,484 Leasehold improvements 7,336 7,134 27,065 25,700 Accumulated depreciation (14,145 ) (11,956 ) Property and equipment, net $ 12,920 $ 13,744

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC Healthcare International OTC Healthcare Household Cleaning Consolidated Balance — March 31, 2015 $ 263,411 $ 20,440 $ 6,800 $ 290,651 Adjustments 305 — — 305 Effects of foreign currency exchange rates — (1,895 ) — (1,895 ) Balance — September 30, 2015 $ 263,716 $ 18,545 $ 6,800 $ 289,061

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Intangible Assets	A reconciliation of the activity affecting intangible assets is as follows: (In thousands) Indefinite Lived Trademarks Finite Lived Trademarks Totals Gross Carrying Amounts Balance — March 31, 2015 $ 1,873,404 $ 358,066 $ 2,231,470 Effects of foreign currency exchange rates (7,988 ) (129 ) (8,117 ) Balance — September 30, 2015 1,865,416 357,937 2,223,353 Accumulated Amortization Balance — March 31, 2015 — 96,770 96,770 Additions — 8,933 8,933 Effects of foreign currency exchange rates — (19 ) (19 ) Balance — September 30, 2015 — 105,684 105,684 Intangible assets, net - September 30, 2015 $ 1,865,416 $ 252,253 $ 2,117,669 Intangible Assets, net by Reportable Segment: North American OTC Healthcare $ 1,676,991 $ 227,627 $ 1,904,618 International OTC Healthcare 78,153 1,076 79,229 Household Cleaning 110,272 23,550 133,822 Intangible assets, net - September 30, 2015 $ 1,865,416 $ 252,253 $ 2,117,669
Schedule of Expected Amortization Expense	At September 30, 2015 , finite-lived intangible assets are being amortized over a period of 10 to 30 years, and the associated amortization expense is expected to be as follows: (In thousands) Year Ending March 31, Amount 2016 (Remaining six months ending March 31, 2016) $ 8,933 2017 17,867 2018 17,867 2019 17,867 2020 17,867 Thereafter 171,852 $ 252,253

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) September 30, March 31, Accrued marketing costs $ 20,909 $ 16,903 Accrued compensation costs 4,655 8,840 Accrued broker commissions 1,082 1,134 Income taxes payable 2,936 2,642 Accrued professional fees 2,214 2,769 Deferred rent 945 1,021 Accrued production costs 5,170 5,610 Accrued lease termination costs 607 669 Other accrued liabilities 3,077 1,360 $ 41,595 $ 40,948

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) September 30, March 31, 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. $ 400,000 $ 400,000 2012 Senior Notes bearing interest at 8.125%, with interest payable on February 1 and August 1 of each year. The 2012 Senior Notes mature on February 1, 2020. 250,000 250,000 2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021. 827,500 877,500 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020. 26,100 66,100 Total long-term debt (including current portion) 1,503,600 1,593,600 Current portion of long-term debt — — Long-term debt 1,503,600 1,593,600 Less: unamortized debt costs (31,736 ) (32,327 ) Long-term debt, net $ 1,471,864 $ 1,561,273
Aggregate Future Principal Payments	As of September 30, 2015, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2012 Senior Notes are as follows: (In thousands) Year Ending March 31, Amount 2016 (remaining six months ending March 31, 2016) $ — 2017 — 2018 — 2019 6,969 2020 258,525 Thereafter 1,238,106 $ 1,503,600

Accumulated Other Comprehensi36

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income	The table below presents accumulated other comprehensive loss (“AOCI”), which affects equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. AOCI consisted of the following at September 30, 2015 and March 31, 2015 : September 30, March 31, (In thousands) 2015 2015 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (34,896 ) $ (23,412 ) Accumulated other comprehensive loss, net of tax $ (34,896 ) $ (23,412 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, (In thousands, except per share data) 2015 2014 2015 2014 Numerator Net income $ 31,803 $ 16,463 $ 57,976 $ 33,195 Denominator Denominator for basic earnings per share — weighted average shares outstanding 52,803 52,088 52,676 52,023 Dilutive effect of unvested restricted stock units and options issued to employees and directors 348 506 379 541 Denominator for diluted earnings per share 53,151 52,594 53,055 52,564 Earnings per Common Share: Basic net earnings per share $ 0.60 $ 0.32 $ 1.10 $ 0.64 Diluted net earnings per share $ 0.60 $ 0.31 $ 1.09 $ 0.63

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Restricted Shares	A summary of the Company's restricted shares granted under the Plan is presented below: Restricted Shares Shares (in thousands) Weighted- Average Grant-Date Fair Value Six months ended September 30, 2014 Vested and nonvested at March 31, 2014 437.5 $ 16.76 Granted 104.4 33.30 Vested and issued (120.7 ) 13.34 Forfeited (14.4 ) 20.78 Vested and nonvested at September 30, 2014 406.8 21.88 Vested at September 30, 2014 76.6 11.62 Six months ended September 30, 2015 Vested and nonvested at March 31, 2015 362.3 $ 22.74 Granted 259.5 42.20 Vested and issued (153.6 ) 18.16 Forfeited (1.4 ) 33.50 Vested and nonvested at September 30, 2015 466.8 35.03 Vested at September 30, 2015 69.8 14.76
Stock Options, Valuation Assumptions	Six Months Ended September 30, 2015 2014 Expected volatility 40.2 % 47.3 % Expected dividends $ — $ — Expected term in years 6.0 6.0 Risk-free rate 1.7 % 2.2 %
Stock Option Activity	A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Six months ended September 30, 2014: Outstanding at March 31, 2014 994.9 $ 15.24 Granted 307.5 33.50 Exercised (284.4 ) 9.70 Forfeited or expired (32.5 ) 25.61 Outstanding at September 30, 2014 985.5 22.19 8.0 $ 10,364 Exercisable at September 30, 2014 416.0 14.31 6.8 7,514 Six months ended September 30, 2015: Outstanding at March 31, 2015 871.2 $ 23.40 Granted 200.1 41.80 Exercised (336.9 ) 18.99 Forfeited or expired (2.1 ) 38.16 Outstanding at September 30, 2015 732.3 30.42 8.1 $ 10,816 Exercisable at September 30, 2015 319.5 21.91 7.0 7,430

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The following summarizes future minimum lease payments for our operating leases as of September 30, 2015 (a) : (In thousands) Year Ending March 31, Facilities Equipment Total 2016 (Remaining six months ending March 31, 2016) $ 887 $ 95 $ 982 2017 1,861 77 1,938 2018 1,871 — 1,871 2019 1,864 — 1,864 2020 1,695 — 1,695 Thereafter 770 — 770 $ 8,948 $ 172 $ 9,120 (a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.3 million due in the future under noncancelable subleases. The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals: (In thousands) September 30, 2015 March 31, 2015 Minimum lease payments $ 9,120 $ 9,957 Less: Sublease rentals (1,283 ) (1,401 ) $ 7,837 $ 8,556
Unrecorded Unconditional Purchase Obligations Disclosure	Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement. (In thousands) Year Ending March 31, Amount 2016 (Remaining six months ending March 31, 2016) 533 2017 1,044 2018 1,013 2019 982 2020 560 Thereafter — $ 4,132

Business Segments (Tables)

Business Segments (Tables)	6 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Information about our Operating and Reportable Segments	The tables below summarize information about our reportable segments. Three Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 165,407 $ 17,433 $ 23,894 $ 206,734 Elimination of intersegment revenues (1,472 ) — — (1,472 ) Third-party segment revenues 163,935 17,433 23,894 205,262 Other revenues 6 — 797 803 Total segment revenues 163,941 17,433 24,691 206,065 Cost of sales 61,499 6,092 18,534 86,125 Gross profit 102,442 11,341 6,157 119,940 Advertising and promotion 24,440 2,777 676 27,893 Contribution margin $ 78,002 $ 8,564 $ 5,481 92,047 Other operating expenses 22,149 Operating income 69,898 Other expense 20,667 Income before income taxes 49,231 Provision for income taxes 17,428 Net income $ 31,803 Six Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 321,746 $ 31,642 $ 45,361 $ 398,749 Elimination of intersegment revenues (2,200 ) — — (2,200 ) Third-party segment revenues 319,546 31,642 45,361 396,549 Other revenues 46 — 1,602 1,648 Total segment revenues 319,592 31,642 46,963 398,197 Cost of sales 119,625 11,382 35,014 166,021 Gross profit 199,967 20,260 11,949 232,176 Advertising and promotion 47,635 5,500 1,180 54,315 Contribution margin $ 152,332 $ 14,760 $ 10,769 177,861 Other operating expenses 45,458 Operating income 132,403 Other expense 43,002 Income before income taxes 89,401 Provision for income taxes 31,425 Net income $ 57,976 Three Months Ended September 30, 2014 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 138,318 $ 17,151 $ 25,246 $ 180,715 Elimination of intersegment revenues (710 ) — — (710 ) Third-party segment revenues 137,608 17,151 25,246 180,005 Other revenues 150 23 1,091 1,264 Total segment revenues 137,758 17,174 26,337 181,269 Cost of sales 52,186 6,601 19,940 78,727 Gross profit 85,572 10,573 6,397 102,542 Advertising and promotion 21,441 3,036 567 25,044 Contribution margin $ 64,131 $ 7,537 $ 5,830 77,498 Other operating expenses 30,980 Operating income 46,518 Other expense 18,193 Income before income taxes 28,325 Provision for income taxes 11,862 Net income $ 16,463 Six Months Ended September 30, 2014 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 249,291 $ 30,843 $ 45,839 $ 325,973 Elimination of intersegment revenues (1,427 ) — — (1,427 ) Third-party segment revenues 247,864 30,843 45,839 324,546 Other revenues 327 58 2,040 2,425 Total segment revenues 248,191 30,901 47,879 326,971 Cost of sales 94,526 11,679 36,358 142,563 Gross profit 153,665 19,222 11,521 184,408 Advertising and promotion 37,794 5,375 971 44,140 Contribution margin $ 115,871 $ 13,847 $ 10,550 140,268 Other operating expenses 50,947 Operating income 89,321 Other expense 32,846 Income before income taxes 56,475 Provision for income taxes 23,280 Net income $ 33,195
Information about our Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,694 $ 688 $ — $ 30,382 Cough & Cold 24,456 4,746 — 29,202 Women's Health 33,607 804 — 34,411 Gastrointestinal 19,061 5,342 — 24,403 Eye & Ear Care 22,690 5,051 — 27,741 Dermatologicals 23,197 611 — 23,808 Oral Care 9,733 189 — 9,922 Other OTC 1,503 2 — 1,505 Household Cleaning — — 24,691 24,691 Total segment revenues $ 163,941 $ 17,433 $ 24,691 $ 206,065 Six Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 56,542 $ 1,218 $ — $ 57,760 Cough & Cold 44,215 9,252 — 53,467 Women's Health 66,515 1,504 — 68,019 Gastrointestinal 39,381 9,150 — 48,531 Eye & Ear Care 47,022 8,981 — 56,003 Dermatologicals 43,292 1,145 — 44,437 Oral Care 19,710 383 — 20,093 Other OTC 2,915 9 — 2,924 Household Cleaning — — 46,963 46,963 Total segment revenues $ 319,592 $ 31,642 $ 46,963 $ 398,197 Three Months Ended September 30, 2014 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,072 $ 792 $ — $ 29,864 Cough & Cold 24,771 5,461 — 30,232 Women's Health 9,119 658 — 9,777 Gastrointestinal 21,075 5,420 — 26,495 Eye & Ear Care 21,405 4,028 — 25,433 Dermatologicals 17,460 687 — 18,147 Oral Care 12,934 127 — 13,061 Other OTC 1,922 1 — 1,923 Household Cleaning — — 26,337 26,337 Total segment revenues $ 137,758 $ 17,174 $ 26,337 $ 181,269 Six Months Ended September 30, 2014 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 54,103 $ 1,457 $ — $ 55,560 Cough & Cold 44,814 10,259 — 55,073 Women's Health 9,487 1,176 — 10,663 Gastrointestinal 41,713 7,917 — 49,630 Eye & Ear Care 42,130 8,670 — 50,800 Dermatologicals 29,720 1,229 — 30,949 Oral Care 23,121 189 — 23,310 Other OTC 3,103 4 — 3,107 Household Cleaning — — 47,879 47,879 Total segment revenues $ 248,191 $ 30,901 $ 47,879 $ 326,971
Allocation of Long-Term Assets to Segments	At September 30, 2015 , approximately 95.9% of our consolidated goodwill and intangible assets were located in the United States and approximately 4.1% were located in Australia. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: (In thousands) North American OTC International OTC Household Cleaning Consolidated Goodwill $ 263,716 $ 18,545 $ 6,800 $ 289,061 Intangible assets Indefinite-lived 1,676,991 78,153 110,272 1,865,416 Finite-lived 227,627 1,076 23,550 252,253 Intangible assets, net 1,904,618 79,229 133,822 2,117,669 Total $ 2,168,334 $ 97,774 $ 140,622 $ 2,406,730

Condensed Consolidating Finan41

Condensed Consolidating Financial Statements (Tables)	6 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Statements of Income and Comprehensive Income	Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,957 $ 164,772 $ 14,005 $ (1,472 ) $ 205,262 Other revenues — 79 798 543 (617 ) 803 Total revenues — 28,036 165,570 14,548 (2,089 ) 206,065 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 10,868 72,120 4,952 (1,815 ) 86,125 Gross profit — 17,168 93,450 9,596 (274 ) 119,940 Operating Expenses Advertising and promotion — 3,204 21,933 2,756 — 27,893 General and administrative 1,199 1,300 12,912 1,051 — 16,462 Depreciation and amortization 1,030 147 4,447 63 — 5,687 Total operating expenses 2,229 4,651 39,292 3,870 — 50,042 Operating income (loss) (2,229 ) 12,517 54,158 5,726 (274 ) 69,898 Other (income) expense Interest income (12,161 ) (21,607 ) (1,169 ) (126 ) 35,030 (33 ) Interest expense 8,964 20,303 25,294 1,169 (35,030 ) 20,700 Equity in (income) loss of subsidiaries (31,441 ) (19,746 ) (3,385 ) — 54,572 — Total other (income) expense (34,638 ) (21,050 ) 20,740 1,043 54,572 20,667 Income (loss) before income taxes 32,409 33,567 33,418 4,683 (54,846 ) 49,231 Provision for income taxes 606 4,892 10,632 1,298 — 17,428 Net income (loss) $ 31,803 $ 28,675 $ 22,786 $ 3,385 $ (54,846 ) $ 31,803 Comprehensive income, net of tax: Currency translation adjustments (11,079 ) (11,079 ) (11,079 ) (11,079 ) 33,237 (11,079 ) Total other comprehensive income (loss) (11,079 ) (11,079 ) (11,079 ) (11,079 ) 33,237 (11,079 ) Comprehensive income (loss) $ 20,724 $ 17,596 $ 11,707 $ (7,694 ) $ (21,609 ) $ 20,724 Condensed Consolidating Statements of Income and Comprehensive Income Six Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 55,840 $ 317,296 $ 25,613 $ (2,200 ) $ 396,549 Other revenues — 175 1,617 1,041 (1,185 ) 1,648 Total revenues — 56,015 318,913 26,654 (3,385 ) 398,197 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 21,309 138,498 9,360 (3,146 ) 166,021 Gross profit — 34,706 180,415 17,294 (239 ) 232,176 Operating Expenses Advertising and promotion — 5,721 43,161 5,433 — 54,315 General and administrative 2,514 3,855 24,863 2,819 — 34,051 Depreciation and amortization 2,019 293 8,892 203 — 11,407 Total operating expenses 4,533 9,869 76,916 8,455 — 99,773 Operating income (loss) (4,533 ) 24,837 103,499 8,839 (239 ) 132,403 Other (income) expense Interest income (24,210 ) (43,015 ) (2,389 ) (238 ) 69,792 (60 ) Interest expense 17,454 42,211 50,349 2,389 (69,792 ) 42,611 Loss on extinguishment of debt — 451 — — — 451 Equity in (income) loss of subsidiaries (56,747 ) (36,701 ) (4,835 ) — 98,283 — Total other (income) expense (63,503 ) (37,054 ) 43,125 2,151 98,283 43,002 Income (loss) before income taxes 58,970 61,891 60,374 6,688 (98,522 ) 89,401 Provision for income taxes 994 8,917 19,661 1,853 — 31,425 Net income (loss) $ 57,976 $ 52,974 $ 40,713 $ 4,835 $ (98,522 ) $ 57,976 Comprehensive income, net of tax: Currency translation adjustments (11,484 ) (11,484 ) (11,484 ) (11,484 ) 34,452 (11,484 ) Total other comprehensive income (loss) (11,484 ) (11,484 ) (11,484 ) (11,484 ) 34,452 (11,484 ) Comprehensive income (loss) $ 46,492 $ 41,490 $ 29,229 $ (6,649 ) $ (64,070 ) $ 46,492 Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended September 30, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,167 $ 138,336 $ 15,212 $ (710 ) $ 180,005 Other revenues — 95 1,241 436 (508 ) 1,264 Total revenues — 27,262 139,577 15,648 (1,218 ) 181,269 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 10,426 64,812 5,767 (2,278 ) 78,727 Gross profit — 16,836 74,765 9,881 1,060 102,542 Operating Expenses Advertising and promotion — 2,699 19,311 3,034 — 25,044 General and administrative 1,109 3,441 20,329 2,249 — 27,128 Depreciation and amortization 870 145 2,729 108 — 3,852 Total operating expenses 1,979 6,285 42,369 5,391 — 56,024 Operating income (loss) (1,979 ) 10,551 32,396 4,490 1,060 46,518 Other (income) expense Interest income (12,245 ) (16,719 ) (1,760 ) (11 ) 30,720 (15 ) Interest expense 8,629 18,208 20,333 1,758 (30,720 ) 18,208 Equity in (income) loss of subsidiaries (17,577 ) (9,825 ) (1,870 ) — 29,272 — Total other (income) expense (21,193 ) (8,336 ) 16,703 1,747 29,272 18,193 Income (loss) before income taxes 19,214 18,887 15,693 2,743 (28,212 ) 28,325 Provision for income taxes 2,751 3,262 4,976 873 — 11,862 Net income (loss) $ 16,463 $ 15,625 $ 10,717 $ 1,870 $ (28,212 ) $ 16,463 Comprehensive income, net of tax: Currency translation adjustments (10,830 ) (10,830 ) (10,830 ) (10,830 ) 32,490 (10,830 ) Total other comprehensive income (loss) (10,830 ) (10,830 ) (10,830 ) (10,830 ) 32,490 (10,830 ) Comprehensive income (loss) $ 5,633 $ 4,795 $ (113 ) $ (8,960 ) $ 4,278 $ 5,633 Condensed Consolidating Statements of Income and Comprehensive Income Six Months Ended September 30, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 52,577 $ 247,234 $ 26,163 $ (1,428 ) $ 324,546 Other revenues — 225 2,340 838 (978 ) 2,425 Total revenues — 52,802 249,574 27,001 (2,406 ) 326,971 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 19,874 115,327 9,790 (2,428 ) 142,563 Gross profit — 32,928 134,247 17,211 22 184,408 Operating Expenses Advertising and promotion — 5,388 33,377 5,375 — 44,140 General and administrative 2,254 5,914 29,319 6,647 — 44,134 Depreciation and amortization 1,512 290 4,818 193 — 6,813 Total operating expenses 3,766 11,592 67,514 12,215 — 95,087 Operating income (loss) (3,766 ) 21,336 66,733 4,996 22 89,321 Other (income) expense Interest income (24,378 ) (30,944 ) (2,522 ) (40 ) 57,837 (47 ) Interest expense 17,177 32,893 38,138 2,522 (57,837 ) 32,893 Equity in (income) loss of subsidiaries (33,256 ) (20,723 ) (911 ) — 54,890 — Total other (income) expense (40,457 ) (18,774 ) 34,705 2,482 54,890 32,846 Income (loss) before income taxes 36,691 40,110 32,028 2,514 (54,868 ) 56,475 Provision for income taxes 3,496 6,979 11,202 1,603 — 23,280 Net income (loss) $ 33,195 $ 33,131 $ 20,826 $ 911 $ (54,868 ) $ 33,195 Comprehensive income, net of tax: Currency translation adjustments (8,104 ) (8,104 ) (8,104 ) (8,104 ) 24,312 (8,104 ) Total other comprehensive income (loss) (8,104 ) (8,104 ) (8,104 ) (8,104 ) 24,312 (8,104 ) Comprehensive income (loss) $ 25,091 $ 25,027 $ 12,722 $ (7,193 ) $ (30,556 ) $ 25,091
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 10,554 $ — $ — $ 11,598 $ — $ 22,152 Accounts receivable, net — 12,810 70,300 8,230 — 91,340 Inventories — 9,684 62,371 6,467 (1,385 ) 77,137 Deferred income tax assets 281 750 6,863 379 — 8,273 Prepaid expenses and other current assets 2,565 543 3,078 691 — 6,877 Total current assets 13,400 23,787 142,612 27,365 (1,385 ) 205,779 Property and equipment, net 9,918 243 2,210 549 — 12,920 Goodwill — 66,007 204,510 18,544 — 289,061 Intangible assets, net — 192,057 1,846,203 79,409 — 2,117,669 Other long-term assets — 1,462 — — — 1,462 Intercompany receivables 1,224,520 2,539,960 822,065 10,880 (4,597,425 ) — Investment in subsidiary 1,588,050 1,253,751 61,703 — (2,903,504 ) — Total Assets $ 2,835,888 $ 4,077,267 $ 3,079,303 $ 136,747 $ (7,502,314 ) $ 2,626,891 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,254 $ 7,453 $ 29,846 $ 2,224 $ — $ 41,777 Accrued interest payable — 9,656 — — — 9,656 Other accrued liabilities 7,875 2,377 27,132 4,211 — 41,595 Total current liabilities 10,129 19,486 56,978 6,435 — 93,028 Long-term debt Principal amount — 1,503,600 — — — 1,503,600 Less unamortized debt costs — (31,736 ) — — — (31,736 ) Long-term debt, net — 1,471,864 — — — 1,471,864 Deferred income tax liabilities — 59,368 314,376 20 — 373,764 Other long-term liabilities — — 2,333 147 — 2,480 Intercompany payables 2,140,004 1,007,264 1,377,646 72,511 (4,597,425 ) — Total Liabilities 2,150,133 2,557,982 1,751,333 79,113 (4,597,425 ) 1,941,136 Stockholders' Equity Common stock 530 — — — — 530 Additional paid-in capital 439,861 1,280,947 1,131,578 74,031 (2,486,556 ) 439,861 Treasury stock, at cost (5,121 ) — — — — (5,121 ) Accumulated other comprehensive income (loss), net of tax (34,896 ) (34,896 ) (34,896 ) (34,896 ) 104,688 (34,896 ) Retained earnings (accumulated deficit) 285,381 273,234 231,288 18,499 (523,021 ) 285,381 Total Stockholders' Equity 685,755 1,519,285 1,327,970 57,634 (2,904,889 ) 685,755 Total Liabilities and Stockholders' Equity $ 2,835,888 $ 4,077,267 $ 3,079,303 $ 136,747 $ (7,502,314 ) $ 2,626,891 Condensed Consolidating Balance Sheet March 31, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 11,387 $ — $ — $ 9,931 $ — $ 21,318 Accounts receivable, net — 14,539 66,523 6,796 — 87,858 Inventories — 8,667 60,297 6,182 (1,146 ) 74,000 Deferred income tax assets 452 674 6,497 474 — 8,097 Prepaid expenses and other current assets 5,731 141 3,804 758 — 10,434 Total current assets 17,570 24,021 137,121 24,141 (1,146 ) 201,707 Property and equipment, net 10,726 175 2,207 636 — 13,744 Goodwill — 66,007 204,205 20,439 — 290,651 Intangible assets, net — 192,325 1,854,798 87,577 — 2,134,700 Other long-term assets — 1,165 — — — 1,165 Intercompany receivables 1,210,017 2,607,054 668,169 8,764 (4,494,004 ) — Investment in subsidiary 1,545,575 1,228,535 65,564 — (2,839,674 ) — Total Assets $ 2,783,888 $ 4,119,282 $ 2,932,064 $ 141,557 $ (7,334,824 ) $ 2,641,967 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 1,959 $ 6,829 $ 32,898 $ 4,429 $ — $ 46,115 Accrued interest payable — 11,974 — — — 11,974 Other accrued liabilities 10,378 1,153 25,795 3,622 — 40,948 Total current liabilities 12,337 19,956 58,693 8,051 — 99,037 Long-term debt Principal amount — 1,593,600 — — — 1,593,600 Less unamortized debt costs — (32,327 ) — — — (32,327 ) Long-term debt, net — 1,561,273 — — — 1,561,273 Deferred income tax liabilities — 59,038 292,504 27 — 351,569 Other long-term liabilities — — 2,293 171 — 2,464 Intercompany payables 2,143,927 1,001,219 1,279,833 69,025 (4,494,004 ) — Total Liabilities 2,156,264 2,641,486 1,633,323 77,274 (4,494,004 ) 2,014,343 Stockholders' Equity Common stock 525 — — — — 525 Additional paid-in capital 426,584 1,280,948 1,131,578 74,031 (2,486,557 ) 426,584 Treasury stock, at cost (3,478 ) — — — — (3,478 ) Accumulated other comprehensive income (loss), net of tax (23,412 ) (23,412 ) (23,412 ) (23,412 ) 70,236 (23,412 ) Retained earnings (accumulated deficit) 227,405 220,260 190,575 13,664 (424,499 ) 227,405 Total Stockholders' Equity 627,624 1,477,796 1,298,741 64,283 (2,840,820 ) 627,624 Total Liabilities and Stockholders' Equity $ 2,783,888 $ 4,119,282 $ 2,932,064 $ 141,557 $ (7,334,824 ) $ 2,641,967
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Six Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 57,976 $ 52,974 $ 40,713 $ 4,835 $ (98,522 ) $ 57,976 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 2,019 293 8,892 203 — 11,407 Deferred income taxes 171 254 21,506 54 — 21,985 Amortization of debt origination costs — 4,055 — — — 4,055 Stock-based compensation costs 4,993 — — 41 — 5,034 Loss on extinguishment of debt — 451 — — — 451 Loss (gain) on sale or disposal of property and equipment — — — (36 ) — (36 ) Equity in income of subsidiaries (56,747 ) (36,701 ) (4,835 ) — 98,283 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — 1,729 (3,550 ) (2,097 ) — (3,918 ) Inventories — (1,017 ) (2,177 ) (883 ) 239 (3,838 ) Prepaid expenses and other current assets 3,166 (402 ) 660 12 — 3,436 Accounts payable 269 624 (3,343 ) (2,069 ) — (4,519 ) Accrued liabilities (2,503 ) (1,094 ) 1,012 1,142 — (1,443 ) Net cash provided by operating activities 9,344 21,166 58,878 1,202 — 90,590 Investing Activities Purchases of property and equipment (1,107 ) (93 ) (103 ) (380 ) — (1,683 ) Proceeds from the sale of property and equipment — — — 344 — 344 Net cash used in investing activities (1,107 ) (93 ) (103 ) (36 ) — (1,339 ) Financing Activities Term loan repayments — (50,000 ) — — — (50,000 ) Borrowings under revolving credit agreement — 15,000 — — — 15,000 Repayments under revolving credit agreement — (55,000 ) — — — (55,000 ) Payments of debt origination costs — (4,211 ) — — — (4,211 ) Proceeds from exercise of stock options 6,398 — — — — 6,398 Proceeds from restricted stock exercises 544 — — — — 544 Excess tax benefits from share-based awards 1,850 — — — — 1,850 Fair value of shares surrendered as payment of tax withholding (2,187 ) — — — — (2,187 ) Intercompany activity, net (15,675 ) 73,138 (58,775 ) 1,312 — — Net cash (used in) provided by financing activities (9,070 ) (21,073 ) (58,775 ) 1,312 — (87,606 ) Effect of exchange rate changes on cash and cash equivalents — — — (811 ) — (811 ) (Decrease) increase in cash and cash equivalents (833 ) — — 1,667 — 834 Cash and cash equivalents - beginning of period 11,387 — — 9,931 — 21,318 Cash and cash equivalents - end of period $ 10,554 $ — $ — $ 11,598 $ — $ 22,152 Condensed Consolidating Statement of Cash Flows Six Months Ended September 30, 2014 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 33,195 $ 33,131 $ 20,826 $ 911 $ (54,868 ) $ 33,195 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 1,512 290 4,818 195 — 6,815 Deferred income taxes (879 ) 1,351 11,084 (60 ) — 11,496 Amortization of debt origination costs — 3,085 — — — 3,085 Stock-based compensation costs 3,403 — — — — 3,403 Loss (gain) on sale or disposal of property and equipment — — — 56 — 56 Equity in income of subsidiaries (33,256 ) (20,723 ) (911 ) — 54,890 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable 466 (107 ) (4,496 ) (4,226 ) — (8,363 ) Inventories — 4,691 1,857 738 (22 ) 7,264 Prepaid expenses and other current assets 5,163 (241 ) (1,718 ) (90 ) — 3,114 Accounts payable (2,332 ) 1,850 (6,997 ) 1,832 — (5,647 ) Accrued liabilities (1,321 ) 3,313 (701 ) 1,349 — 2,640 Net cash provided by operating activities 5,951 26,640 23,762 705 — 57,058 Investing Activities Purchases of property and equipment (1,127 ) — (87 ) (166 ) — (1,380 ) Proceeds from sale of business — — 18,500 — — 18,500 Acquisition of Insight Pharmaceuticals, less cash acquired — — (749,666 ) — — (749,666 ) Acquisition of the Hydralyte brand — — — (77,991 ) — (77,991 ) Intercompany activity, net — (809,157 ) 731,166 77,991 — — Net cash used in investing activities (1,127 ) (809,157 ) (87 ) (166 ) — (810,537 ) Financing Activities Term loan borrowings — 720,000 — — — 720,000 Term loan repayments — (25,000 ) — — — (25,000 ) Borrowings under revolving credit agreement — 124,600 — — — 124,600 Repayments under revolving credit agreement — (58,500 ) — — — (58,500 ) Payment of debt origination costs — (16,072 ) — — — (16,072 ) Proceeds from exercise of stock options 2,757 — — — — 2,757 Proceeds from restricted stock exercises 57 — — — — 57 Excess tax benefits from share-based awards 1,030 — — — — 1,030 Fair value of shares surrendered as payment of tax withholding (1,660 ) — — — — (1,660 ) Intercompany activity, net (21,187 ) 37,489 (18,641 ) 2,339 — — Net cash provided by (used in) financing activities (19,003 ) 782,517 (18,641 ) 2,339 — 747,212 Effect of exchange rate changes on cash and cash equivalents — — — (316 ) — (316 ) (Decrease) increase in cash and cash equivalents (14,179 ) — 5,034 2,562 — (6,583 ) Cash and cash equivalents - beginning of period 24,644 — — 3,687 — 28,331 Cash and cash equivalents - end of period $ 10,465 $ — $ 5,034 $ 6,249 $ — $ 21,748

Business and Basis of Present42

Business and Basis of Presentation (Other Balance Sheet and Income Statement Items) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage, subsidiaries	100.00%		100.00%
Term of original maturities, cash equivalents, up to and including			3 months
Shipping, warehousing and handling costs	$ 10.4	$ 9.4	$ 19.1	$ 17.1

Business and Basis of Present43

Business and Basis of Presentation (Property and Equipment) (Details)	6 Months Ended
	Sep. 30, 2015
Machinery
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years

Business and Basis of Present44

Business and Basis of Presentation (Intangible Assets) (Details)	6 Months Ended
	Sep. 30, 2015
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years

Business and Basis of Present45

Business and Basis of Presentation (Debt Issuance Costs) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Debt Instrument [Line Items]
Other long-term assets	$ (1,462)	$ (1,165)
Adjustments for new accounting pronouncement
Debt Instrument [Line Items]
Other long-term assets		$ 27,400

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) $ in Thousands	Sep. 03, 2014USD ($)brand	Sep. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Apr. 30, 2014USD ($)
Business Acquisition [Line Items]
Purchased amortizable intangible assets, weighted average remaining period		14 years 1 month 6 days
Goodwill		$ 289,061	$ 290,651
Insight Pharmaceuticals
Business Acquisition [Line Items]
Purchase price of acquisition	$ 753,200
Number of pharmaceutical brands acquired as a result of acquisition | brand	27
Number of brands sold | brand	1
Non-amortizable intangible assets	$ 599,600
Amortizable intangible assets	124,800
Purchased amortizable intangible assets, weighted average useful life		16 years 2 months 12 days
Purchased amortizable intangible assets, weighted average remaining period		15 years 1 month 2 days
Goodwill	103,560
Value of assets sold on acquisition date, excluded from purchase price	18,500
Non-amortizable intangible assets	724,374
Insight Pharmaceuticals | Intangible assets
Business Acquisition [Line Items]
Value of assets sold on acquisition date, excluded from purchase price	17,700
Insight Pharmaceuticals | Inventory
Business Acquisition [Line Items]
Value of assets sold on acquisition date, excluded from purchase price	600
Insight Pharmaceuticals | Property, plant and equipment
Business Acquisition [Line Items]
Value of assets sold on acquisition date, excluded from purchase price	$ 200
Hydralyte
Business Acquisition [Line Items]
Goodwill				$ 1,224
Non-amortizable intangible assets				$ 73,580

Acquisitions (Allocation of Ass

Acquisitions (Allocation of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015	Sep. 03, 2014	Apr. 30, 2014
Purchase Price
Goodwill	$ 289,061	$ 290,651
Insight Pharmaceuticals
Purchase Price
Cash acquired			$ 3,507
Accounts receivable			26,012
Inventories			23,456
Deferred income tax assets - current			1,032
Prepaids and other current assets			1,341
Property, plant and equipment			2,308
Goodwill			103,560
Intangible assets			724,374
Total assets acquired			885,590
Accounts payable			16,079
Accrued expenses			8,539
Deferred income tax liabilities - long term			107,799
Total liabilities assumed			132,417
Net assets acquired			$ 753,173
Hydralyte
Purchase Price
Inventories				$ 1,970
Property, plant and equipment				1,267
Goodwill				1,224
Intangible assets				73,580
Total assets acquired				78,041
Accrued expenses				38
Other long term liabilities				12
Total liabilities assumed				50
Net assets acquired				$ 77,991

Acquisitions (Pro Forma) (Detai

Acquisitions (Pro Forma) (Details) - Insight Pharmaceuticals $ / shares in Units, $ in Thousands	6 Months Ended
	Sep. 30, 2014USD ($)$ / shares
Business Acquisition, Pro Forma Information [Abstract]
Revenues	$ 393,140
Net income	$ 37,957
Earnings per share:
Basic (in dollars per share) | $ / shares	$ 0.73
Diluted (in dollars per share) | $ / shares	$ 0.72

Accounts Receivable (Details)

Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 101,069	$ 97,764
Less allowances for discounts, returns and uncollectible accounts	(9,729)	(9,906)
Accounts receivable, net	91,340	87,858
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	99,324	95,411
Other receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 1,745	$ 2,353

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 6,428	$ 7,588
Finished goods	70,709	66,412
Inventories	77,137	74,000
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 3,500	$ 4,100

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Components of Property and Equipment
Property and equipment, gross	$ 27,065		$ 27,065		$ 25,700
Accumulated depreciation	(14,145)		(14,145)		(11,956)
Property and equipment, net	12,920		12,920		13,744
Depreciation	1,200	$ 900	2,500	$ 1,600
Machinery
Components of Property and Equipment
Property and equipment, gross	4,056		4,056		4,743
Computer equipment
Components of Property and Equipment
Property and equipment, gross	13,300		13,300		11,339
Furniture and fixtures
Components of Property and Equipment
Property and equipment, gross	2,373		2,373		2,484
Leasehold improvements
Components of Property and Equipment
Property and equipment, gross	$ 7,336		$ 7,336		$ 7,134

Goodwill (Details)

Goodwill (Details) $ in Thousands	6 Months Ended
	Sep. 30, 2015USD ($)
Goodwill [Roll Forward]
Balance — March 31, 2015	$ 290,651
Adjustments	305
Effects of foreign currency exchange rates	(1,895)
Balance — September 30, 2015	289,061
North American OTC Healthcare
Goodwill [Roll Forward]
Balance — March 31, 2015	263,411
Adjustments	305
Effects of foreign currency exchange rates	0
Balance — September 30, 2015	263,716
International OTC Healthcare
Goodwill [Roll Forward]
Balance — March 31, 2015	20,440
Adjustments	0
Effects of foreign currency exchange rates	(1,895)
Balance — September 30, 2015	18,545
Household Cleaning
Goodwill [Roll Forward]
Balance — March 31, 2015	6,800
Adjustments	0
Effects of foreign currency exchange rates	0
Balance — September 30, 2015	$ 6,800

Goodwill (Narrative) (Details)

Goodwill (Narrative) (Details) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2015USD ($)	Sep. 30, 2015USD ($)	Mar. 31, 2015USD ($)business	Sep. 03, 2014USD ($)	Apr. 30, 2014USD ($)
Goodwill [Line Items]
Number of acquisitions | business			2
Goodwill		$ 289,061	$ 290,651
Goodwill adjustments		$ 305
Insight Pharmaceuticals
Goodwill [Line Items]
Goodwill				$ 103,560
Goodwill adjustments	$ 300
Hydralyte
Goodwill [Line Items]
Goodwill					$ 1,224

Intangible Assets (Schedule of

Intangible Assets (Schedule of Reconciliation of Activity Affecting Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Mar. 31, 2015
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	$ 1,865,416	$ 1,865,416
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Totals, accumulated amortization, additions	4,400	8,933
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates		(19)
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance		2,231,470
Totals, effects of foreign currency exchange rate		(8,117)
Totals, gross, ending balance	2,223,353	2,223,353
Intangible Assets, Accumulated Amortization [Abstract]
Totals, accumulated amortization, beginning balance		96,770
Totals, accumulated amortization, additions	4,400	8,933
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates		(19)
Totals, accumulated amortization, ending balance	105,684	105,684
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	252,253	252,253
Intangible Assets, Net [Abstract]
Intangible assets, net	2,117,669	2,117,669	$ 2,134,700
North American OTC Healthcare
Intangible Assets, Net [Abstract]
Intangible assets, net	1,904,618	1,904,618
International OTC Healthcare
Intangible Assets, Net [Abstract]
Intangible assets, net	79,229	79,229
Household Cleaning
Intangible Assets, Net [Abstract]
Intangible assets, net	133,822	133,822
Finite Lived Trademarks
Finite-Lived Intangible Assets, Gross [Abstract]
Finite Lived Trademarks, beginning balance		358,066
Finite Lived Trademarks, effects of foreign currency exchange rate		(129)
Finite Lived Trademarks, ending balance	357,937	357,937
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite Lived Trademarks, accumulated amortization, beginning balance		96,770
Totals, accumulated amortization, additions		8,933
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates		(19)
Finite Lived Trademarks, accumulated amortization, ending balance	105,684	105,684
Intangible Assets, Accumulated Amortization [Abstract]
Totals, accumulated amortization, additions		8,933
Finite Lived Trademarks, accumulated amortization, effects of foreign exchange rates		(19)
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	252,253	252,253
Finite Lived Trademarks | North American OTC Healthcare
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	227,627	227,627
Finite Lived Trademarks | International OTC Healthcare
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	1,076	1,076
Finite Lived Trademarks | Household Cleaning
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	23,550	23,550
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		1,873,404
Indefinite Lived Trademarks, effects of foreign currency exchange rate		(7,988)
Indefinite Lived Trademarks, ending balance	1,865,416	1,865,416
Indefinite Lived Trademarks | North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	1,676,991	1,676,991
Indefinite Lived Trademarks | International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	78,153	78,153
Indefinite Lived Trademarks | Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, ending balance	$ 110,272	$ 110,272

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) $ in Thousands	Sep. 03, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2015USD ($)	Mar. 31, 2015business	Apr. 30, 2014USD ($)
Finite-Lived Intangible Assets [Line Items]
Number of acquisitions | business				2
Weighted average remaining life for finite-lived intangible assets			14 years 1 month 6 days
Amortization expense		$ 4,400	$ 8,933
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives			10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives			30 years
Insight Pharmaceuticals
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 724,374
Acquired intangible assets sold on acquisition date	$ 17,700
Weighted average remaining life for finite-lived intangible assets			15 years 1 month 2 days
Hydralyte
Finite-Lived Intangible Assets [Line Items]
Intangible assets					$ 73,580

Intangible Assets (Expected Amo

Intangible Assets (Expected Amortization Expense) (Details) $ in Thousands	Sep. 30, 2015USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2016 (Remaining six months ending March 31, 2016)	$ 8,933
2,017	17,867
2,018	17,867
2,019	17,867
2,020	17,867
Thereafter	171,852
Intangible assets, net	$ 252,253

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued marketing costs	$ 20,909	$ 16,903
Accrued compensation costs	4,655	8,840
Accrued broker commissions	1,082	1,134
Income taxes payable	2,936	2,642
Accrued professional fees	2,214	2,769
Deferred rent	945	1,021
Accrued production costs	5,170	5,610
Accrued lease termination costs	607	669
Other accrued liabilities	3,077	1,360
Total other accrued liabilities	$ 41,595	$ 40,948

Long-Term Debt (2012 Senior Not

Long-Term Debt (2012 Senior Notes) (Details) - USD ($)	Sep. 30, 2015	Mar. 31, 2015	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Percentage of subsidiary owned			100.00%	100.00%
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount				$ 250,000,000
Debt instrument, stated interest rate (percent)	8.125%	8.125%		8.125%
Debt issuance costs capitalized				$ 12,600,000

Long-Term Debt (2012 Term Loan

Long-Term Debt (2012 Term Loan and 2012 ABL Revolver) (Details) - USD ($)	Jun. 09, 2015	May. 08, 2015	Sep. 03, 2014	Feb. 21, 2013	Jan. 31, 2012	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Dec. 17, 2013
Debt Instrument [Line Items]
Percentage of subsidiary owned					100.00%						100.00%
Loss on extinguishment of debt						$ 0	$ 0		$ 451,000	$ 0
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, maturity term					5 years
Line of credit facility, maximum borrowing capacity					$ 50,000,000	135,000,000			135,000,000
Line of credit facility, increase in borrowing capacity						$ 85,000,000			$ 85,000,000
Debt instrument, interest rate, increase/(decrease) (percent)										(0.25%)
Debt instrument, average interest rate during period (percent)									2.20%
Line of credit facility, commitment fee percentage			0.50%
Line of credit facility, conditional commitment fee percentage			0.375%
2012 ABL Revolver | Revolving Credit Facility | LIBOR
Debt Instrument [Line Items]
Debt instrument, variable rate (percent)			1.75%
2012 ABL Revolver | Revolving Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (percent)			2.00%
2012 ABL Revolver | Revolving Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (percent)			2.25%
2012 ABL Revolver | Revolving Credit Facility | Base Rate
Debt Instrument [Line Items]
Debt instrument, variable rate (percent)			0.75%
2012 ABL Revolver | Revolving Credit Facility | Base Rate | Minimum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (percent)			1.00%
2012 ABL Revolver | Revolving Credit Facility | Base Rate | Maximum
Debt Instrument [Line Items]
Debt instrument, conditional variable rate (percent)			1.25%
2012 ABL Revolver | Revolving Credit Facility | Base Rate | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (percent)			1.00%
2012 ABL Revolver | Revolving Credit Facility | Base Rate | Federal Funds Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (percent)			0.50%
Term Loan and ABL Revolver 2012
Debt Instrument [Line Items]
Debt issuance costs capitalized					20,600,000
2012 ABL Revolver Amendment 3 | Revolving Credit Facility
Debt Instrument [Line Items]
Line of credit facility, increase in borrowing capacity			$ 40,000,000
Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount					$ 660,000,000
Debt instrument, maturity term					7 years
Debt instrument, discount, percentage					1.50%
Proceeds from issuance of long-term debt					$ 650,100,000
Debt instrument, average interest rate during period (percent)									4.60%
Debt instrument, quarterly payment, percent of original principal amount (percent)			0.25%
Term Loans | 2012 Term Loan | LIBOR | Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)					0.75%
Term Loans | 2012 Term Loan | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (percent)					1.75%
Term Loans | 2012 Term Loan | Base Rate | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (percent)					1.00%
Term Loans | 2012 Term Loan | Base Rate | Federal Funds Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, fixed component (percent)					0.50%
Term Loans | Amendment 1, 2012 Term Loan
Debt Instrument [Line Items]
Loss on extinguishment of debt								$ 1,400,000
Term Loans | Amendment 1, 2012 Term Loan | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)				2.75%
Debt instrument, reference rate floor (percent)				1.00%
Term Loans | Amendment 1, 2012 Term Loan | Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)				2.00%
Term Loans | Amendment 2, 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)			1.00%
Term Loans | Amendment 2, 2012 Term Loan | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)			3.125%
Term Loans | Amendment 2, 2012 Term Loan | Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)			2.00%
2012 ABL Revolver | Amendment 4, 2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Debt instrument, maturity term	5 years
Line of credit facility, increase in borrowing capacity	$ 35,000,000
Term B-2 | Amendment 2, 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount			$ 720,000,000
Term B-2 | Amendment 2, 2012 Term Loan | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)			3.50%
Debt instrument, reference rate floor (percent)			1.00%
Debt instrument, step down interest rate (percent)			3.25%
Term B-2 | Amendment 2, 2012 Term Loan | Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)			2.00%
Term B-2 | Amendment 3, 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount		$ 645,000,000
Loans Payable, Term B-3 | Amendment 3, 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount		$ 852,500,000
Debt instrument, quarterly payment, percent of original principal amount (percent)		0.25%
Loans Payable, Term B-3 | Amendment 3, 2012 Term Loan | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate (percent)		2.75%
Debt instrument, stated interest rate, minimum (percent)		0.75%
Loans Payable, Term B-3 | Amendment 3, 2012 Term Loan | Base Rate
Debt Instrument [Line Items]
Debt instrument, stated interest rate, minimum (percent)		1.75%
Loans Payable, Term B-1 | Amendment 3, 2012 Term Loan
Debt Instrument [Line Items]
Debt instrument, face amount		$ 207,500,000

Long-Term Debt (2013 Senior Not

Long-Term Debt (2013 Senior Notes) (Details) - USD ($)	Sep. 30, 2015	Mar. 31, 2015	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Percentage of subsidiary owned			100.00%	100.00%
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount			$ 400,000,000
Debt instrument, stated interest rate (percent)	5.375%	5.375%	5.375%
Debt issuance costs capitalized			$ 7,200,000

Long-Term Debt (Redemptions and

Long-Term Debt (Redemptions and Restrictions) (Details) - USD ($) $ in Thousands	Jan. 31, 2012	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Debt Instrument [Line Items]
Other long-term assets		$ (1,462)		$ (1,165)
Debt instrument, unamortized discount		31,736		32,327
Repayments of long-term debt		50,000	$ 25,000
Adjustments for new accounting pronouncement
Debt Instrument [Line Items]
Other long-term assets				$ 27,400
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Repayments of long-term debt		26,100
Remaining borrowing capacity		87,200
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Unamortized debt issuance expense and discount		$ 7,900
Senior Notes | 2012 Senior Notes | Prior to February 1, 2016
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	100.00%
Senior Notes | 2012 Senior Notes | Prior to February 1, 2015
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	108.125%
Debt instrument, percentage of principal amount eligible for redemption	35.00%
Senior Notes | 2012 Senior Notes | Upon Change in Control
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	101.00%
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		101.00%
Unamortized debt issuance expense and discount		$ 5,900
Senior Notes | 2013 Senior Notes | Prior to December 15, 2016
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		100.00%
Debt instrument, percentage of principal amount eligible for redemption		35.00%
Senior Notes | 2013 Senior Notes | On Or After December 15, 2016
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage		105.375%
Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Unamortized debt issuance expense and discount		$ 17,900

Long-Term Debt (Schedule of Lon

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015	Dec. 17, 2013	Jan. 31, 2012
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,503,600	$ 1,593,600
Current portion of long-term debt	0	0
Principal amount	1,503,600	1,593,600
Less: unamortized debt costs	(31,736)	(32,327)
Long-term debt, net	1,471,864	1,561,273
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 26,100	$ 66,100
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	5.375%	5.375%	5.375%
Long-term debt, gross	$ 400,000	$ 400,000
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	8.125%	8.125%		8.125%
Long-term debt, gross	$ 250,000	$ 250,000
Loans Payable, Term B-3 | 2012 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	$ 827,500	$ 877,500
Loans Payable, Term B-3 | 2012 Senior Notes | Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)	1.75%	1.75%
Loans Payable, Term B-3 | 2012 Senior Notes | LIBOR
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)	0.75%	0.75%

Long-Term Debt (Maturities of L

Long-Term Debt (Maturities of Long-term Debt) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Debt Disclosure [Abstract]
2016 (remaining six months ending March 31, 2016)	$ 0
2,017	0
2,018	0
2,019	6,969
2,020	258,525
Thereafter	1,238,106
Long-term debt, gross	$ 1,503,600	$ 1,593,600

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Millions	Sep. 30, 2015	Mar. 31, 2015
2012 ABL Revolver | Market Value | Fair Value, Inputs, Level 2 | Revolving Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	$ 26	$ 65.7
2012 ABL Revolver | Carrying Value | Revolving Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Line of credit, fair value disclosure	26.1	66.1
Senior Notes | 2013 Senior Notes | Market Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	391	405
Senior Notes | 2013 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	400	400
Senior Notes | 2012 Senior Notes | Market Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	263.8	268.1
Senior Notes | 2012 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	250	250
Term Loans | 2012 Term Loan | Market Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	827.5	880.5
Term Loans | 2012 Term Loan | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loans payable, fair value disclosure	$ 827.5	$ 877.5

Stockholders' Equity (Details)

Stockholders' Equity (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2015vote$ / sharesshares	Sep. 30, 2014shares	Sep. 30, 2015vote$ / sharesshares	Sep. 30, 2014$ / sharesshares	Mar. 31, 2015$ / sharesshares
Class of Stock [Line Items]
Common stock, shares authorized | shares	250,000,000		250,000,000		250,000,000
Common stock, par value (in USD per share)	$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares authorized | shares	5,000,000		5,000,000		5,000,000
Preferred stock, par value (in USD per share)	$ 0.01		$ 0.01		$ 0.01
Voting rights, number of votes per common share owned | vote	1		1
Restricted Shares
Class of Stock [Line Items]
Restricted stock repurchased during period, shares | shares	0	13,924	39,429	47,664
Restricted stock acquired, average cost per share (in USD per share)			$ 41.66	$ 33.63

Accumulated Other Comprehensi66

Accumulated Other Comprehensive Loss (Components of AOCI) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Cumulative translation adjustment	$ (34,896)	$ (23,412)
Accumulated other comprehensive loss, net of tax	$ (34,896)	$ (23,412)

(Earnings Per Share) (Details)

(Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Numerator
Net income	$ 31,803	$ 16,463	$ 57,976	$ 33,195
Denominator
Denominator for basic earnings per share — weighted average shares outstanding	52,803	52,088	52,676	52,023
Dilutive effect of unvested restricted stock units and options issued to employees and directors	348	506	379	541
Denominator for diluted earnings per share (in shares)	53,151	52,594	53,055	52,564
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ 0.60	$ 0.32	$ 1.10	$ 0.64
Diluted net earnings per share (in USD per share)	$ 0.60	$ 0.31	$ 1.09	$ 0.63

Earnings Per Share (Antidilutiv

Earnings Per Share (Antidilutive Securities) (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, shares	0.2	0.3	0.2	0.3

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) $ / shares in Units, $ in Millions	Aug. 04, 2015shares	Jul. 01, 2015$ / sharesshares	Jun. 01, 2015USD ($)	May. 11, 2015$ / sharesshares	Apr. 22, 2015shares	May. 31, 2014shares	Jun. 30, 2014shares	Sep. 30, 2015USD ($)shares	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)$ / sharesshares
Share-based Compensation, Aggregate Disclosures:
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan								5,000,000		5,000,000
Share-based compensation costs charged against income | $								$ 2	$ 1.5	$ 5	$ 3.4
Tax benefit recognized from share-based compensation expense | $								0.7	$ 0.5	$ 1.8	$ 1.2
Stock options granted (in shares)										200,100	307,500
Exercise price of granted awards (in USD per share) | $ / shares										$ 41.80	$ 33.50
Options, Additional Disclosures:
Options granted, weighted-average grant-date fair value (in USD per share) | $ / shares										$ 17.10	$ 15.93
Options exercised, aggregate intrinsic value | $										$ 8.3
Unrecognized compensation costs related to nonvested awards | $								$ 13.3		$ 13.3
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition										1 year 2 months 12 days
Total fair value of vested shares | $										$ 6.5	$ 4.2
Cash received from exercise of stock options | $										6.4	2.8
Tax benefit realized from exercise of stock options | $										$ 2	$ 1.8
Shares available for issuance under the Plan								2,600,000		2,600,000
Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Granted in period (in shares)	2,075	2,841		185,904						259,500	104,400
Award vesting period		3 years
Period following director's term in which RSUs may be settled	6 months
Restricted Shares
Granted, weighted-average grant-date fair value (in USD per share) | $ / shares										$ 42.20	$ 33.30
Restricted Stock Units (RSUs) | Share-based compensation award, tranche 1
Share-based Compensation, Aggregate Disclosures:
Granted in period (in shares)				163,404
Award vesting period				3 years
Restricted Stock Units (RSUs) | Share-based compensation award, tranche 2
Share-based Compensation, Aggregate Disclosures:
Granted in period (in shares)				22,500
Award vesting period				3 years
Annual award vesting percentage				33.30%
Stock Options
Share-based Compensation, Aggregate Disclosures:
Granted in period (in shares)		13,861
Stock options granted (in shares)				186,302
Award vesting period		3 years		3 years
Annual award vesting percentage		33.30%		33.30%
Term from grant date, exercisable		10 years		10 years
Exercise price of granted awards (in USD per share) | $ / shares		$ 46.58		$ 41.44
Stock Options | Minimum
Share-based Compensation, Aggregate Disclosures:
Award vesting period										3 years
Stock Options | Maximum
Share-based Compensation, Aggregate Disclosures:
Award vesting period										5 years
Options, Additional Disclosures:
Award exercisability period, from date of grant										10 years
Restricted Shares
Restricted Shares
Granted, weighted-average grant-date fair value (in USD per share) | $ / shares										$ 42.20	$ 33.30
Restricted Shares | Minimum
Share-based Compensation, Aggregate Disclosures:
Award vesting period										3 years
Restricted Shares | Maximum
Share-based Compensation, Aggregate Disclosures:
Award vesting period										5 years
President and CEO
Share-based Compensation, Aggregate Disclosures:
Accelerated share-based compensation expense | $			$ 0.8
Granted in period (in shares)					57,924
Employee | Restricted Shares
Share-based Compensation, Aggregate Disclosures:
Award vesting period										3 years
Director | Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Granted in period (in shares)				362
Number of common shares into which each RSU may be converted (in shares)	1
Director | Restricted Shares
Share-based Compensation, Aggregate Disclosures:
Award vesting period										1 year
2005 Long-Term Incentive Plan
Share-based Compensation, Aggregate Disclosures:
Number of additional shares authorized							1,800,000
Maximum number of shares per participant, 12 month period						1,000,000	2,500,000
Extension of plan term							10 years

Share-Based Compensation (Restr

Share-Based Compensation (Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) - $ / shares	Aug. 04, 2015	Jul. 01, 2015	May. 11, 2015	Sep. 30, 2015	Sep. 30, 2014
Shares
Outstanding, beginning of period (in shares)				362,300	437,500
Granted (in shares)	2,075	2,841	185,904	259,500	104,400
Vested and issued (in shares)				(153,600)	(120,700)
Forfeited (in shares)				(1,400)	(14,400)
Outstanding, end of period (in shares)				466,800	406,800
Vested, end of period (in shares)				69,800	76,600
Weighted- Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)				$ 22.74	$ 16.76
Granted, weighted-average grant-date fair value (in USD per share)				42.20	33.30
Vested and issued, weighted-average grant-date fair value (in USD per share)				18.16	13.34
Forfeited, weighted-average grant-date fair value (in USD per share)				33.50	20.78
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)				35.03	21.88
Vested, end of period, weighted-average grant-date fair value (in USD per share)				$ 14.76	$ 11.62

Share-Based Compensation (Stock

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($)	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	40.20%	47.30%
Expected dividends	$ 0	$ 0
Expected term in years	6 years	6 years
Risk-free rate	1.70%	2.20%

Share-Based Compensation (Sto72

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Shares
Outstanding, beginning of period (in shares)	871,200	994,900
Granted (in shares)	200,100	307,500
Exercised (in shares)	(336,900)	(284,400)
Forfeited or expired (in shares)	(2,100)	(32,500)
Outstanding, end of period (in shares)	732,300	985,500
Exercisable, end of period (in shares)	319,500	416,000
Weighted- Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 23.40	$ 15.24
Granted, weighted-average exercise price (in USD per share)	41.80	33.50
Exercised, weighted-average exercise price (in USD per share)	18.99	9.70
Forfeited or expired, weighted-average exercise price (in USD per share)	38.16	25.61
Outstanding, end of period, weighted-average exercise price (in USD per share)	30.42	22.19
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 21.91	$ 14.31
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	8 years 1 month 6 days	8 years 1 day
Exercisable, end of period, weighted-average remaining contractual term	7 years	6 years 9 months 1 day
Outstanding, end of period, aggregate intrinsic value	$ 10,816	$ 10,364
Exercisable, end of period, aggregate intrinsic value	$ 7,430	$ 7,514

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Effective income tax rate (percent)	35.40%	41.90%	35.20%	41.20%
Ownership percentage, subsidiaries	100.00%		100.00%
Net operating loss carryforwards	$ 44.6		$ 44.6
Operating loss carryforwards, limitation on use, annual amount	33.6		33.6
Uncertain tax liability	$ 3.4		$ 3.4		$ 3.4

Commitments and Contingencies74

Commitments and Contingencies (Future Minimum Rental Payments) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Operating Leased Assets [Line Items]
2016 (Remaining six months ending March 31, 2016)	$ 982		$ 982
2,017	1,938		1,938
2,018	1,871		1,871
2,019	1,864		1,864
2,020	1,695		1,695
Thereafter	770		770
Total future minimum payments due	9,120		9,120		$ 9,957
Future minimum sublease rentals	1,300		1,300
Less: Sublease rentals	(1,283)		(1,283)		(1,401)
Minimum lease payments, less minimum sublease rentals	7,837		7,837		$ 8,556
Rent expense	400	$ 300	800	$ 700
Facilities
Operating Leased Assets [Line Items]
2016 (Remaining six months ending March 31, 2016)	887		887
2,017	1,861		1,861
2,018	1,871		1,871
2,019	1,864		1,864
2,020	1,695		1,695
Thereafter	770		770
Total future minimum payments due	8,948		8,948
Equipment
Operating Leased Assets [Line Items]
2016 (Remaining six months ending March 31, 2016)	95		95
2,017	77		77
2,018	0		0
2,019	0		0
2,020	0		0
Thereafter	0		0
Total future minimum payments due	$ 172		$ 172

Commitments and Contingencies75

Commitments and Contingencies (Long-term Supply Agreement) (Details) - Third-party Manufacturing - USD ($) $ in Thousands	Nov. 01, 2009	Sep. 30, 2015
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years
2016 (Remaining six months ending March 31, 2016)		$ 533
2,017		1,044
2,018		1,013
2,019		982
2,020		560
Thereafter		0
Total purchase commitment		$ 4,132

Concentrations of Risk (Details

Concentrations of Risk (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2015manufacturer	Sep. 30, 2014brandmanufacturer	Sep. 30, 2015brandmanufacturercustomer	Sep. 30, 2014manufacturer
Concentration Risk [Line Items]
Number of third-party manufacturers	102	101	102	101
Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	41.70%	40.60%	42.80%	41.20%
Number of highest selling brands comprising group against which concentration risk is measured | brand		5	5
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	19.60%	17.00%	19.70%	18.00%
Number of customers exceeding concentration risk benchmark | customer			1
Sales | Customer Concentration Risk | Customer No. 2
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%		9.70%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			81.30%	77.40%
Number of third-party manufacturers with long-term contracts			48	47
Accounts Receivable | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage			20.90%

Business Segments (Information

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information, Profit (Loss):
Net sales	$ 205,262	$ 180,005	$ 396,549	$ 324,546
Other revenues	803	1,264	1,648	2,425
Total revenues	206,065	181,269	398,197	326,971
Cost of sales	86,125	78,727	166,021	142,563
Gross profit	119,940	102,542	232,176	184,408
Advertising and promotion	27,893	25,044	54,315	44,140
Contribution margin	92,047	77,498	177,861	140,268
Other operating expenses	22,149	30,980	45,458	50,947
Operating income	69,898	46,518	132,403	89,321
Other expense	20,667	18,193	43,002	32,846
Income before income taxes	49,231	28,325	89,401	56,475
Provision for income taxes	17,428	11,862	31,425	23,280
Net income	$ 31,803	$ 16,463	$ 57,976	$ 33,195
Geographic Concentration Risk | Sales | United States
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	85.80%	82.70%	86.50%	83.50%
Geographic Concentration Risk | Sales | Canada
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	5.50%	7.40%	5.30%	6.60%
Geographic Concentration Risk | Sales | Australia
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage	6.80%	8.10%	6.30%	7.60%
Geographic Concentration Risk | Goodwill and Intangible Assets | United States
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage			95.90%
Geographic Concentration Risk | Goodwill and Intangible Assets | Australia
Geographic Areas, Revenues from External Customers [Abstract]
Concentration risk, percentage			4.10%
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	$ 163,935	$ 137,608	$ 319,546	$ 247,864
Other revenues	6	150	46	327
Total revenues	163,941	137,758	319,592	248,191
Cost of sales	61,499	52,186	119,625	94,526
Gross profit	102,442	85,572	199,967	153,665
Advertising and promotion	24,440	21,441	47,635	37,794
Contribution margin	78,002	64,131	152,332	115,871
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	17,433	17,151	31,642	30,843
Other revenues	0	23	0	58
Total revenues	17,433	17,174	31,642	30,901
Cost of sales	6,092	6,601	11,382	11,679
Gross profit	11,341	10,573	20,260	19,222
Advertising and promotion	2,777	3,036	5,500	5,375
Contribution margin	8,564	7,537	14,760	13,847
Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	23,894	25,246	45,361	45,839
Other revenues	797	1,091	1,602	2,040
Total revenues	24,691	26,337	46,963	47,879
Cost of sales	18,534	19,940	35,014	36,358
Gross profit	6,157	6,397	11,949	11,521
Advertising and promotion	676	567	1,180	971
Contribution margin	5,481	5,830	10,769	10,550
Operating Segments
Segment Reporting Information, Profit (Loss):
Net sales	206,734	180,715	398,749	325,973
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	165,407	138,318	321,746	249,291
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	17,433	17,151	31,642	30,843
Operating Segments | Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	23,894	25,246	45,361	45,839
Intersegment Eliminations
Segment Reporting Information, Profit (Loss):
Net sales	(1,472)	(710)	(2,200)	(1,427)
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	(1,472)	(710)	(2,200)	(1,427)
Intersegment Eliminations | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Net sales	0	0	0	0
Intersegment Eliminations | Household Cleaning
Segment Reporting Information, Profit (Loss):
Net sales	$ 0	$ 0	$ 0	$ 0

Business Segments (Revenue by P

Business Segments (Revenue by Product) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue from External Customer [Line Items]
Revenues	$ 206,065	$ 181,269	$ 398,197	$ 326,971
Analgesics
Revenue from External Customer [Line Items]
Revenues	30,382	29,864	57,760	55,560
Cough & Cold
Revenue from External Customer [Line Items]
Revenues	29,202	30,232	53,467	55,073
Women's Health
Revenue from External Customer [Line Items]
Revenues	34,411	9,777	68,019	10,663
Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	24,403	26,495	48,531	49,630
Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	27,741	25,433	56,003	50,800
Dermatologicals
Revenue from External Customer [Line Items]
Revenues	23,808	18,147	44,437	30,949
Oral Care
Revenue from External Customer [Line Items]
Revenues	9,922	13,061	20,093	23,310
Other OTC
Revenue from External Customer [Line Items]
Revenues	1,505	1,923	2,924	3,107
Household Cleaning
Revenue from External Customer [Line Items]
Revenues	24,691	26,337	46,963	47,879
North American OTC Healthcare
Revenue from External Customer [Line Items]
Revenues	163,941	137,758	319,592	248,191
North American OTC Healthcare | Analgesics
Revenue from External Customer [Line Items]
Revenues	29,694	29,072	56,542	54,103
North American OTC Healthcare | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	24,456	24,771	44,215	44,814
North American OTC Healthcare | Women's Health
Revenue from External Customer [Line Items]
Revenues	33,607	9,119	66,515	9,487
North American OTC Healthcare | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	19,061	21,075	39,381	41,713
North American OTC Healthcare | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	22,690	21,405	47,022	42,130
North American OTC Healthcare | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	23,197	17,460	43,292	29,720
North American OTC Healthcare | Oral Care
Revenue from External Customer [Line Items]
Revenues	9,733	12,934	19,710	23,121
North American OTC Healthcare | Other OTC
Revenue from External Customer [Line Items]
Revenues	1,503	1,922	2,915	3,103
International OTC Healthcare
Revenue from External Customer [Line Items]
Revenues	17,433	17,174	31,642	30,901
International OTC Healthcare | Analgesics
Revenue from External Customer [Line Items]
Revenues	688	792	1,218	1,457
International OTC Healthcare | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	4,746	5,461	9,252	10,259
International OTC Healthcare | Women's Health
Revenue from External Customer [Line Items]
Revenues	804	658	1,504	1,176
International OTC Healthcare | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	5,342	5,420	9,150	7,917
International OTC Healthcare | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	5,051	4,028	8,981	8,670
International OTC Healthcare | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	611	687	1,145	1,229
International OTC Healthcare | Oral Care
Revenue from External Customer [Line Items]
Revenues	189	127	383	189
International OTC Healthcare | Other OTC
Revenue from External Customer [Line Items]
Revenues	2	1	9	4
Household Cleaning
Revenue from External Customer [Line Items]
Revenues	24,691	26,337	46,963	47,879
Household Cleaning | Analgesics
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Cough & Cold
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Women's Health
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Gastrointestinal
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Eye & Ear Care
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Dermatologicals
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Oral Care
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Other OTC
Revenue from External Customer [Line Items]
Revenues	0	0	0	0
Household Cleaning | Household Cleaning
Revenue from External Customer [Line Items]
Revenues	$ 24,691	$ 26,337	$ 46,963	$ 47,879

Business Segments (Assets by Se

Business Segments (Assets by Segment) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 289,061	$ 290,651
Indefinite-lived intangibles	1,865,416
Finite-lived intangibles	252,253
Intangible assets, net	2,117,669	2,134,700
Intangible assets, net (including goodwill)	2,406,730
Finite-lived
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived intangibles	252,253
Indefinite-lived
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived intangibles	1,865,416	1,873,404
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	263,716	263,411
Intangible assets, net	1,904,618
Intangible assets, net (including goodwill)	2,168,334
North American OTC Healthcare | Finite-lived
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived intangibles	227,627
North American OTC Healthcare | Indefinite-lived
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived intangibles	1,676,991
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	18,545	20,440
Intangible assets, net	79,229
Intangible assets, net (including goodwill)	97,774
International OTC Healthcare | Finite-lived
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived intangibles	1,076
International OTC Healthcare | Indefinite-lived
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived intangibles	78,153
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	6,800	$ 6,800
Intangible assets, net	133,822
Intangible assets, net (including goodwill)	140,622
Household Cleaning | Finite-lived
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived intangibles	23,550
Household Cleaning | Indefinite-lived
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived intangibles	$ 110,272

Condensed Consolidating Finan80

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues
Net sales	$ 205,262	$ 180,005	$ 396,549	$ 324,546
Other revenues	803	1,264	1,648	2,425
Total revenues	206,065	181,269	398,197	326,971
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	86,125	78,727	166,021	142,563
Gross profit	119,940	102,542	232,176	184,408
Operating Expenses
Advertising and promotion	27,893	25,044	54,315	44,140
General and administrative	16,462	27,128	34,051	44,134
Depreciation and amortization	5,687	3,852	11,407	6,813
Total operating expenses	50,042	56,024	99,773	95,087
Operating income	69,898	46,518	132,403	89,321
Other (income) expense
Interest income	(33)	(15)	(60)	(47)
Interest expense	20,700	18,208	42,611	32,893
Loss on extinguishment of debt	0	0	451	0
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	20,667	18,193	43,002	32,846
Income before income taxes	49,231	28,325	89,401	56,475
Provision for income taxes	17,428	11,862	31,425	23,280
Net income	31,803	16,463	57,976	33,195
Comprehensive income, net of tax:
Currency translation adjustments	(11,079)	(10,830)	(11,484)	(8,104)
Total other comprehensive loss	(11,079)	(10,830)	(11,484)	(8,104)
Comprehensive income	20,724	5,633	46,492	25,091
Prestige Brands Holdings, Inc.
Revenues
Net sales	0	0	0	0
Other revenues	0	0	0	0
Total revenues	0	0	0	0
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	0	0	0	0
Gross profit	0	0	0	0
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	1,199	1,109	2,514	2,254
Depreciation and amortization	1,030	870	2,019	1,512
Total operating expenses	2,229	1,979	4,533	3,766
Operating income	(2,229)	(1,979)	(4,533)	(3,766)
Other (income) expense
Interest income	(12,161)	(12,245)	(24,210)	(24,378)
Interest expense	8,964	8,629	17,454	17,177
Loss on extinguishment of debt			0
Equity in (income) loss of subsidiaries	(31,441)	(17,577)	(56,747)	(33,256)
Total other expense	(34,638)	(21,193)	(63,503)	(40,457)
Income before income taxes	32,409	19,214	58,970	36,691
Provision for income taxes	606	2,751	994	3,496
Net income	31,803	16,463	57,976	33,195
Comprehensive income, net of tax:
Currency translation adjustments	(11,079)	(10,830)	(11,484)	(8,104)
Total other comprehensive loss	(11,079)	(10,830)	(11,484)	(8,104)
Comprehensive income	20,724	5,633	46,492	25,091
Prestige Brands, Inc., the issuer or the borrower
Revenues
Net sales	27,957	27,167	55,840	52,577
Other revenues	79	95	175	225
Total revenues	28,036	27,262	56,015	52,802
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	10,868	10,426	21,309	19,874
Gross profit	17,168	16,836	34,706	32,928
Operating Expenses
Advertising and promotion	3,204	2,699	5,721	5,388
General and administrative	1,300	3,441	3,855	5,914
Depreciation and amortization	147	145	293	290
Total operating expenses	4,651	6,285	9,869	11,592
Operating income	12,517	10,551	24,837	21,336
Other (income) expense
Interest income	(21,607)	(16,719)	(43,015)	(30,944)
Interest expense	20,303	18,208	42,211	32,893
Loss on extinguishment of debt			451
Equity in (income) loss of subsidiaries	(19,746)	(9,825)	(36,701)	(20,723)
Total other expense	(21,050)	(8,336)	(37,054)	(18,774)
Income before income taxes	33,567	18,887	61,891	40,110
Provision for income taxes	4,892	3,262	8,917	6,979
Net income	28,675	15,625	52,974	33,131
Comprehensive income, net of tax:
Currency translation adjustments	(11,079)	(10,830)	(11,484)	(8,104)
Total other comprehensive loss	(11,079)	(10,830)	(11,484)	(8,104)
Comprehensive income	17,596	4,795	41,490	25,027
Combined Subsidiary Guarantors
Revenues
Net sales	164,772	138,336	317,296	247,234
Other revenues	798	1,241	1,617	2,340
Total revenues	165,570	139,577	318,913	249,574
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	72,120	64,812	138,498	115,327
Gross profit	93,450	74,765	180,415	134,247
Operating Expenses
Advertising and promotion	21,933	19,311	43,161	33,377
General and administrative	12,912	20,329	24,863	29,319
Depreciation and amortization	4,447	2,729	8,892	4,818
Total operating expenses	39,292	42,369	76,916	67,514
Operating income	54,158	32,396	103,499	66,733
Other (income) expense
Interest income	(1,169)	(1,760)	(2,389)	(2,522)
Interest expense	25,294	20,333	50,349	38,138
Loss on extinguishment of debt			0
Equity in (income) loss of subsidiaries	(3,385)	(1,870)	(4,835)	(911)
Total other expense	20,740	16,703	43,125	34,705
Income before income taxes	33,418	15,693	60,374	32,028
Provision for income taxes	10,632	4,976	19,661	11,202
Net income	22,786	10,717	40,713	20,826
Comprehensive income, net of tax:
Currency translation adjustments	(11,079)	(10,830)	(11,484)	(8,104)
Total other comprehensive loss	(11,079)	(10,830)	(11,484)	(8,104)
Comprehensive income	11,707	(113)	29,229	12,722
Combined Non-Guarantor Subsidiaries
Revenues
Net sales	14,005	15,212	25,613	26,163
Other revenues	543	436	1,041	838
Total revenues	14,548	15,648	26,654	27,001
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	4,952	5,767	9,360	9,790
Gross profit	9,596	9,881	17,294	17,211
Operating Expenses
Advertising and promotion	2,756	3,034	5,433	5,375
General and administrative	1,051	2,249	2,819	6,647
Depreciation and amortization	63	108	203	193
Total operating expenses	3,870	5,391	8,455	12,215
Operating income	5,726	4,490	8,839	4,996
Other (income) expense
Interest income	(126)	(11)	(238)	(40)
Interest expense	1,169	1,758	2,389	2,522
Loss on extinguishment of debt			0
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	1,043	1,747	2,151	2,482
Income before income taxes	4,683	2,743	6,688	2,514
Provision for income taxes	1,298	873	1,853	1,603
Net income	3,385	1,870	4,835	911
Comprehensive income, net of tax:
Currency translation adjustments	(11,079)	(10,830)	(11,484)	(8,104)
Total other comprehensive loss	(11,079)	(10,830)	(11,484)	(8,104)
Comprehensive income	(7,694)	(8,960)	(6,649)	(7,193)
Eliminations
Revenues
Net sales	(1,472)	(710)	(2,200)	(1,428)
Other revenues	(617)	(508)	(1,185)	(978)
Total revenues	(2,089)	(1,218)	(3,385)	(2,406)
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	(1,815)	(2,278)	(3,146)	(2,428)
Gross profit	(274)	1,060	(239)	22
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	0	0	0	0
Depreciation and amortization	0	0	0	0
Total operating expenses	0	0	0	0
Operating income	(274)	1,060	(239)	22
Other (income) expense
Interest income	35,030	30,720	69,792	57,837
Interest expense	(35,030)	(30,720)	(69,792)	(57,837)
Loss on extinguishment of debt			0
Equity in (income) loss of subsidiaries	54,572	29,272	98,283	54,890
Total other expense	54,572	29,272	98,283	54,890
Income before income taxes	(54,846)	(28,212)	(98,522)	(54,868)
Provision for income taxes	0	0	0	0
Net income	(54,846)	(28,212)	(98,522)	(54,868)
Comprehensive income, net of tax:
Currency translation adjustments	33,237	32,490	34,452	24,312
Total other comprehensive loss	33,237	32,490	34,452	24,312
Comprehensive income	$ (21,609)	$ 4,278	$ (64,070)	$ (30,556)

Condensed Consolidating Finan81

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Mar. 31, 2014
Condensed Financial Statements, Captions [Line Items]
Ownership percentage, subsidiaries	100.00%
Current assets
Cash and cash equivalents	$ 22,152	$ 21,318	$ 21,748	$ 28,331
Accounts receivable, net	91,340	87,858
Inventories	77,137	74,000
Deferred income tax assets	8,273	8,097
Prepaid expenses and other current assets	6,877	10,434
Total current assets	205,779	201,707
Property and equipment, net	12,920	13,744
Goodwill	289,061	290,651
Intangible assets, net	2,117,669	2,134,700
Other long-term assets	1,462	1,165
Intercompany receivables	0	0
Investment in subsidiary	0	0
Total Assets	2,626,891	2,641,967
Current liabilities
Accounts payable	41,777	46,115
Accrued interest payable	9,656	11,974
Other accrued liabilities	41,595	40,948
Total current liabilities	93,028	99,037
Long-term debt
Principal amount	1,503,600	1,593,600
Less unamortized debt costs	(31,736)	(32,327)
Long-term debt, net	1,471,864	1,561,273
Deferred income tax liabilities	373,764	351,569
Other long-term liabilities	2,480	2,464
Intercompany payables	0	0
Total Liabilities	1,941,136	2,014,343
Stockholders' Equity
Common stock	530	525
Additional paid-in capital	439,861	426,584
Treasury stock, at cost	(5,121)	(3,478)
Accumulated other comprehensive loss, net of tax	(34,896)	(23,412)
Retained earnings (accumulated deficit)	285,381	227,405
Total Stockholders' Equity	685,755	627,624
Total Liabilities and Stockholders' Equity	2,626,891	2,641,967
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	10,554	11,387	10,465	24,644
Accounts receivable, net	0	0
Inventories	0	0
Deferred income tax assets	281	452
Prepaid expenses and other current assets	2,565	5,731
Total current assets	13,400	17,570
Property and equipment, net	9,918	10,726
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	1,224,520	1,210,017
Investment in subsidiary	1,588,050	1,545,575
Total Assets	2,835,888	2,783,888
Current liabilities
Accounts payable	2,254	1,959
Accrued interest payable	0	0
Other accrued liabilities	7,875	10,378
Total current liabilities	10,129	12,337
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	2,140,004	2,143,927
Total Liabilities	2,150,133	2,156,264
Stockholders' Equity
Common stock	530	525
Additional paid-in capital	439,861	426,584
Treasury stock, at cost	(5,121)	(3,478)
Accumulated other comprehensive loss, net of tax	(34,896)	(23,412)
Retained earnings (accumulated deficit)	285,381	227,405
Total Stockholders' Equity	685,755	627,624
Total Liabilities and Stockholders' Equity	2,835,888	2,783,888
Prestige Brands, Inc., the issuer or the borrower
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	12,810	14,539
Inventories	9,684	8,667
Deferred income tax assets	750	674
Prepaid expenses and other current assets	543	141
Total current assets	23,787	24,021
Property and equipment, net	243	175
Goodwill	66,007	66,007
Intangible assets, net	192,057	192,325
Other long-term assets	1,462	1,165
Intercompany receivables	2,539,960	2,607,054
Investment in subsidiary	1,253,751	1,228,535
Total Assets	4,077,267	4,119,282
Current liabilities
Accounts payable	7,453	6,829
Accrued interest payable	9,656	11,974
Other accrued liabilities	2,377	1,153
Total current liabilities	19,486	19,956
Long-term debt
Principal amount	1,503,600	1,593,600
Less unamortized debt costs	(31,736)	(32,327)
Long-term debt, net	1,471,864	1,561,273
Deferred income tax liabilities	59,368	59,038
Other long-term liabilities	0	0
Intercompany payables	1,007,264	1,001,219
Total Liabilities	2,557,982	2,641,486
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,280,947	1,280,948
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	(34,896)	(23,412)
Retained earnings (accumulated deficit)	273,234	220,260
Total Stockholders' Equity	1,519,285	1,477,796
Total Liabilities and Stockholders' Equity	4,077,267	4,119,282
Combined Subsidiary Guarantors
Current assets
Cash and cash equivalents	0	0	5,034	0
Accounts receivable, net	70,300	66,523
Inventories	62,371	60,297
Deferred income tax assets	6,863	6,497
Prepaid expenses and other current assets	3,078	3,804
Total current assets	142,612	137,121
Property and equipment, net	2,210	2,207
Goodwill	204,510	204,205
Intangible assets, net	1,846,203	1,854,798
Other long-term assets	0	0
Intercompany receivables	822,065	668,169
Investment in subsidiary	61,703	65,564
Total Assets	3,079,303	2,932,064
Current liabilities
Accounts payable	29,846	32,898
Accrued interest payable	0	0
Other accrued liabilities	27,132	25,795
Total current liabilities	56,978	58,693
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	314,376	292,504
Other long-term liabilities	2,333	2,293
Intercompany payables	1,377,646	1,279,833
Total Liabilities	1,751,333	1,633,323
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,131,578	1,131,578
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	(34,896)	(23,412)
Retained earnings (accumulated deficit)	231,288	190,575
Total Stockholders' Equity	1,327,970	1,298,741
Total Liabilities and Stockholders' Equity	3,079,303	2,932,064
Combined Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	11,598	9,931	6,249	3,687
Accounts receivable, net	8,230	6,796
Inventories	6,467	6,182
Deferred income tax assets	379	474
Prepaid expenses and other current assets	691	758
Total current assets	27,365	24,141
Property and equipment, net	549	636
Goodwill	18,544	20,439
Intangible assets, net	79,409	87,577
Other long-term assets	0	0
Intercompany receivables	10,880	8,764
Investment in subsidiary	0	0
Total Assets	136,747	141,557
Current liabilities
Accounts payable	2,224	4,429
Accrued interest payable	0	0
Other accrued liabilities	4,211	3,622
Total current liabilities	6,435	8,051
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	20	27
Other long-term liabilities	147	171
Intercompany payables	72,511	69,025
Total Liabilities	79,113	77,274
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	74,031	74,031
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	(34,896)	(23,412)
Retained earnings (accumulated deficit)	18,499	13,664
Total Stockholders' Equity	57,634	64,283
Total Liabilities and Stockholders' Equity	136,747	141,557
Eliminations
Current assets
Cash and cash equivalents	0	0	$ 0	$ 0
Accounts receivable, net	0	0
Inventories	(1,385)	(1,146)
Deferred income tax assets	0	0
Prepaid expenses and other current assets	0	0
Total current assets	(1,385)	(1,146)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	(4,597,425)	(4,494,004)
Investment in subsidiary	(2,903,504)	(2,839,674)
Total Assets	(7,502,314)	(7,334,824)
Current liabilities
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	(4,597,425)	(4,494,004)
Total Liabilities	(4,597,425)	(4,494,004)
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	(2,486,556)	(2,486,557)
Treasury stock, at cost	0	0
Accumulated other comprehensive loss, net of tax	104,688	70,236
Retained earnings (accumulated deficit)	(523,021)	(424,499)
Total Stockholders' Equity	(2,904,889)	(2,840,820)
Total Liabilities and Stockholders' Equity	$ (7,502,314)	$ (7,334,824)

Condensed Consolidating Finan82

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating Activities
Net income (loss)	$ 31,803	$ 16,463	$ 57,976	$ 33,195
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			11,407	6,815
Deferred income taxes			21,985	11,496
Amortization of debt origination costs			4,055	3,085
Stock-based compensation costs			5,034	3,403
Loss on extinguishment of debt	0	0	451	0
Loss (gain) on sale or disposal of property and equipment			(36)	56
Equity in income of subsidiaries	0	0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			(3,918)	(8,363)
Inventories			(3,838)	7,264
Prepaid expenses and other current assets			3,436	3,114
Accounts payable			(4,519)	(5,647)
Accrued liabilities			(1,443)	2,640
Net cash provided by operating activities			90,590	57,058
Investing Activities
Purchases of property and equipment			(1,683)	(1,380)
Proceeds from the sale of property and equipment			344	0
Proceeds from sale of business			0	18,500
Acquisition of Insight Pharmaceuticals, less cash acquired				(749,666)
Acquisition of the Hydralyte brand				(77,991)
Intercompany activity, net				0
Net cash used in investing activities			(1,339)	(810,537)
Financing Activities
Term loan borrowings				720,000
Term loan repayments			(50,000)	(25,000)
Borrowings under revolving credit agreement			15,000	124,600
Repayments under revolving credit agreement			(55,000)	(58,500)
Payments of debt origination costs			(4,211)	(16,072)
Proceeds from exercise of stock options			6,398	2,757
Proceeds from restricted stock exercises			544	57
Excess tax benefits from share-based awards			1,850	1,030
Fair value of shares surrendered as payment of tax withholding			(2,187)	(1,660)
Intercompany activity, net			0	0
Net cash (used in) provided by financing activities			(87,606)	747,212
Effects of exchange rate changes on cash and cash equivalents			(811)	(316)
Increase (decrease) in cash and cash equivalents			834	(6,583)
Cash and cash equivalents - beginning of period			21,318	28,331
Cash and cash equivalents - end of period	22,152	21,748	22,152	21,748
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)	31,803	16,463	57,976	33,195
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			2,019	1,512
Deferred income taxes			171	(879)
Amortization of debt origination costs			0	0
Stock-based compensation costs			4,993	3,403
Loss on extinguishment of debt			0
Loss (gain) on sale or disposal of property and equipment			0	0
Equity in income of subsidiaries	(31,441)	(17,577)	(56,747)	(33,256)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			0	466
Inventories			0	0
Prepaid expenses and other current assets			3,166	5,163
Accounts payable			269	(2,332)
Accrued liabilities			(2,503)	(1,321)
Net cash provided by operating activities			9,344	5,951
Investing Activities
Purchases of property and equipment			(1,107)	(1,127)
Proceeds from the sale of property and equipment			0
Proceeds from sale of business				0
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				0
Intercompany activity, net				0
Net cash used in investing activities			(1,107)	(1,127)
Financing Activities
Term loan borrowings				0
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			6,398	2,757
Proceeds from restricted stock exercises			544	57
Excess tax benefits from share-based awards			1,850	1,030
Fair value of shares surrendered as payment of tax withholding			(2,187)	(1,660)
Intercompany activity, net			(15,675)	(21,187)
Net cash (used in) provided by financing activities			(9,070)	(19,003)
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase (decrease) in cash and cash equivalents			(833)	(14,179)
Cash and cash equivalents - beginning of period			11,387	24,644
Cash and cash equivalents - end of period	10,554	10,465	10,554	10,465
Prestige Brands, Inc., the issuer or the borrower
Operating Activities
Net income (loss)	28,675	15,625	52,974	33,131
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			293	290
Deferred income taxes			254	1,351
Amortization of debt origination costs			4,055	3,085
Stock-based compensation costs			0	0
Loss on extinguishment of debt			451
Loss (gain) on sale or disposal of property and equipment			0	0
Equity in income of subsidiaries	(19,746)	(9,825)	(36,701)	(20,723)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			1,729	(107)
Inventories			(1,017)	4,691
Prepaid expenses and other current assets			(402)	(241)
Accounts payable			624	1,850
Accrued liabilities			(1,094)	3,313
Net cash provided by operating activities			21,166	26,640
Investing Activities
Purchases of property and equipment			(93)	0
Proceeds from the sale of property and equipment			0
Proceeds from sale of business				0
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				0
Intercompany activity, net				(809,157)
Net cash used in investing activities			(93)	(809,157)
Financing Activities
Term loan borrowings				720,000
Term loan repayments			(50,000)	(25,000)
Borrowings under revolving credit agreement			15,000	124,600
Repayments under revolving credit agreement			(55,000)	(58,500)
Payments of debt origination costs			(4,211)	(16,072)
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises			0	0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			73,138	37,489
Net cash (used in) provided by financing activities			(21,073)	782,517
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase (decrease) in cash and cash equivalents			0	0
Cash and cash equivalents - beginning of period			0	0
Cash and cash equivalents - end of period	0	0	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)	22,786	10,717	40,713	20,826
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			8,892	4,818
Deferred income taxes			21,506	11,084
Amortization of debt origination costs			0	0
Stock-based compensation costs			0	0
Loss on extinguishment of debt			0
Loss (gain) on sale or disposal of property and equipment			0	0
Equity in income of subsidiaries	(3,385)	(1,870)	(4,835)	(911)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			(3,550)	(4,496)
Inventories			(2,177)	1,857
Prepaid expenses and other current assets			660	(1,718)
Accounts payable			(3,343)	(6,997)
Accrued liabilities			1,012	(701)
Net cash provided by operating activities			58,878	23,762
Investing Activities
Purchases of property and equipment			(103)	(87)
Proceeds from the sale of property and equipment			0
Proceeds from sale of business				18,500
Acquisition of Insight Pharmaceuticals, less cash acquired				(749,666)
Acquisition of the Hydralyte brand				0
Intercompany activity, net				731,166
Net cash used in investing activities			(103)	(87)
Financing Activities
Term loan borrowings				0
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises			0	0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			(58,775)	(18,641)
Net cash (used in) provided by financing activities			(58,775)	(18,641)
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase (decrease) in cash and cash equivalents			0	5,034
Cash and cash equivalents - beginning of period			0	0
Cash and cash equivalents - end of period	0	5,034	0	5,034
Combined Non-Guarantor Subsidiaries
Operating Activities
Net income (loss)	3,385	1,870	4,835	911
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			203	195
Deferred income taxes			54	(60)
Amortization of debt origination costs			0	0
Stock-based compensation costs			41	0
Loss on extinguishment of debt			0
Loss (gain) on sale or disposal of property and equipment			(36)	56
Equity in income of subsidiaries	0	0	0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			(2,097)	(4,226)
Inventories			(883)	738
Prepaid expenses and other current assets			12	(90)
Accounts payable			(2,069)	1,832
Accrued liabilities			1,142	1,349
Net cash provided by operating activities			1,202	705
Investing Activities
Purchases of property and equipment			(380)	(166)
Proceeds from the sale of property and equipment			344
Proceeds from sale of business				0
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				(77,991)
Intercompany activity, net				77,991
Net cash used in investing activities			(36)	(166)
Financing Activities
Term loan borrowings				0
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises			0	0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			1,312	2,339
Net cash (used in) provided by financing activities			1,312	2,339
Effects of exchange rate changes on cash and cash equivalents			(811)	(316)
Increase (decrease) in cash and cash equivalents			1,667	2,562
Cash and cash equivalents - beginning of period			9,931	3,687
Cash and cash equivalents - end of period	11,598	6,249	11,598	6,249
Eliminations
Operating Activities
Net income (loss)	(54,846)	(28,212)	(98,522)	(54,868)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			0	0
Deferred income taxes			0	0
Amortization of debt origination costs			0	0
Stock-based compensation costs			0	0
Loss on extinguishment of debt			0
Loss (gain) on sale or disposal of property and equipment			0	0
Equity in income of subsidiaries	54,572	29,272	98,283	54,890
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			0	0
Inventories			239	(22)
Prepaid expenses and other current assets			0	0
Accounts payable			0	0
Accrued liabilities			0	0
Net cash provided by operating activities			0	0
Investing Activities
Purchases of property and equipment			0	0
Proceeds from the sale of property and equipment			0
Proceeds from sale of business				0
Acquisition of Insight Pharmaceuticals, less cash acquired				0
Acquisition of the Hydralyte brand				0
Intercompany activity, net				0
Net cash used in investing activities			0	0
Financing Activities
Term loan borrowings				0
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises			0	0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			0	0
Net cash (used in) provided by financing activities			0	0
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase (decrease) in cash and cash equivalents			0	0
Cash and cash equivalents - beginning of period			0	0
Cash and cash equivalents - end of period	$ 0	$ 0	$ 0	$ 0

Subsequent Events (Details)

Subsequent Events (Details) - $ / shares	Oct. 28, 2015	Aug. 04, 2015	Jul. 01, 2015	May. 11, 2015	Sep. 30, 2015	Sep. 30, 2014
Subsequent Event [Line Items]
Stock options granted (in shares)					200,100	307,500
Exercise price of granted awards (in USD per share)					$ 41.80	$ 33.50
Restricted Stock Units (RSUs)
Subsequent Event [Line Items]
Granted in period (in shares)		2,075	2,841	185,904	259,500	104,400
Award vesting period			3 years
Subsequent event
Subsequent Event [Line Items]
Award vesting period	3 years
Subsequent event | Chief Financial Officer
Subsequent Event [Line Items]
Stock options granted (in shares)	8,079
Annual award vesting percentage	33.30%
Term from grant date, exercisable	10 years
Exercise price of granted awards (in USD per share)	$ 50.42
Subsequent event | Restricted Stock Units (RSUs) | Chief Financial Officer
Subsequent Event [Line Items]
Granted in period (in shares)	6,612